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Background-—Although macrophage migration inhibitory factor (MIF) has been demonstrated to mediate cardioprotection in
ischemia/reperfusion injury and antagonize ﬁbrotic effects through its receptor, CD74, the function of the soluble CD74 receptor
ectodomain (sCD74) and its interaction with circulating MIF have not been explored in cardiac disease.
Methods and Results-—Cardiac ﬁbroblasts were isolated from hearts of neonatal mice and differentiated into myoﬁbroblasts. Co-
treatment with recombinant MIF and sCD74 induced cell death (P<0.001), which was mediated by receptor-interacting serine/
threonine-protein kinase (RIP)1/RIP3-dependent necroptosis (P=0.0376). This effect was speciﬁc for cardiac ﬁbroblasts and did
not affect cardiomyocytes. Gene expression analyses using microarray and RT-qPCR technology revealed a 4-fold upregulation of
several interferon-induced genes upon co-treatment of myoﬁbroblasts with sCD74 and MIF (Iﬁ44: P=0.011; Irg1: P=0.022; Clec4e:
P=0.011). Furthermore, Western blot analysis conﬁrmed the role of sCD74 as a modulator of MIF signaling by diminishing MIF-
mediated protein kinase B (AKT) activation (P=0.0197) and triggering p38 activation (P=0.0641). We obtained evidence that sCD74
inhibits MIF-mediated survival pathway through the C-X-C chemokine receptor 4/AKT axis, enabling the induction of CD74-
dependent necroptotic processes in cardiac myoﬁbroblasts. Preliminary clinical data revealed a lowered sCD74/MIF ratio in heart
failure patients (17.4710.09 versus 1.4130.6244).
Conclusions-—These ﬁndings suggest that treatment of cardiac myoﬁbroblasts with sCD74 and MIF induces necroptosis, offering
new insights into the mechanism of myoﬁbroblast depletion during scar maturation. Preliminary clinical data provided ﬁrst
evidence about a clinical relevance of the sCD74/MIF axis in heart failure, suggesting that these proteins may be a promising
target to modulate cardiac remodeling and disease progression in heart failure. ( J Am Heart Assoc. 2018;7:e009384. DOI: 10.
1161/JAHA.118.009384.)
Key Words: cell death • heart failure • macrophage migration inhibitory factor • myocardial ﬁbrosis • myoﬁbroblast
• necroptosis • soluble CD74
T he healthcare system is burdened with an increasingincidence of coronary heart disease (CHD), which is the
leading cause of morbidity and mortality in the Western
world.1,2 Numerous CHD patients, who experienced and
survived a myocardial infarction (MI) event, consequently
suffer from adverse ventricular remodeling and heart fail-
ure (HF), requiring intensive treatment strategies and
hospitalization.2,3
MI-associated remodeling of the myocardium is required
for maintaining cardiac function and integrity.4 Immediately
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after an ischemic insult, cardiac remodeling is initiated by a
transient inﬂammatory response triggered through danger-
associated molecular (DAMP) patterns and cytokines released
from injured cardiomyocytes, attracting immune cells into the
infarcted area.5,6 Once the wound is “cleared” and the
inﬂammatory phase is repressed, ﬁbroblasts are activated and
recruited, followed by their proliferation and differentiation
into myoﬁbroblasts.7,8 Myoﬁbroblasts express and deposit
large amounts of collagen to renew the extracellular matrix
(ECM) compartment, therefore ensuring the integrity of the
heart tissue.9,10 However, persistence and sustained activa-
tion of myoﬁbroblasts, especially in uninfarcted but vulnerable
areas, accounts for expansion of the ﬁbrotic core and adverse
ventricular remodeling. Additionally, myoﬁbroblasts are the
major site of matrix metalloproteinases (MMPs) synthesis in
the myocardium.11,12 An increased MMP activity is
observed in the myocardium of humans and animals with
HF disease,13–15 underlining their key role in pathological
cardiac remodeling by directly degrading ECM, which corre-
lates with ventricular dilatation followed by a decrease in
cardiac tensile strength.16 This, in turn, leads to cardiac
dysfunction and ultimately to HF with adverse clinical effects
on patients’ mid- to long-term outcome.9,17
The stress-regulating chemokine-like cytokine, macro-
phage migration inhibitory factor (MIF) features danger-
associated molecular pattern–like characteristics and is an
important upstream regulator of the innate immune
response.18–20 Although it generally promotes acute and
chronic inﬂammatory processes, MIF has been demonstrated
to also exhibit protective effects during myocardial ischemia/
reperfusion injury, especially in the ischemic and early
reperfusion phase. Similarly, the role of MIF in cardiac
remodeling also appears to be dichotomous.21 On the one
hand, MIF promotes postinfarct rupture and remodeling by
promoting inﬁltration of immune cells as well as expression of
proinﬂammatory and ﬁbrosis-related proteins.21,22 On the
other hand, MIF depletion has been reported to delay post-MI
healing and to worsen aging-induced cardiac remodeling and
ﬁbrosis in myocardial hypertrophy.21,23,24
Cardioprotection by MIF is mediated through its intrinsic
antioxidant capacity and by signaling through its cognate
receptor CD74, a type II transmembrane glycoprotein and the
surface form of class II invariant chain.25–31 In fact, The MIF/
CD74/AMPK (adenosine monophosphate kinase) signaling
pathway has repeatedly been demonstrated to play a pivotal
protective role in acute myocardial ischemia/reperfusion
injury.31–33 MIF also signals through the chemokine recep-
tors, C-X-C chemokine receptor (CXCR)2 and CXCR4,34 and
has been found to exhibit compartmentalized protective and
detrimental effects through CXCR2 receptor in a mouse
model of myocardial ischemia/reperfusion.35 Whereas the C-
X-C motif chemokine ligand 12/CXCR4 axis also has a
double-edged role in experimental MI, the contribution of the
MIF/CXCR4 ligand/receptor axis has not yet been directly
studied in the heart.36
Recently, it was demonstrated that a soluble CD74
(sCD74) fragment is released from the cell surface of liver
cells by ectodomain shedding to modulate MIF-dependent
activities.37 Ectodomain shedding represents an important
posttranslational modiﬁcation event that downregulates cell-
surface expression of various receptors and liberates biolog-
ically active fragments that often exhibit a function that is
distinct from that of the membrane-bound receptor form.38
Although the effects of the intracellular domain of CD74,
released following regulated intracellular proteolysis, have
been extensively studied,39–41 we are only beginning to
understand the functions of the CD74 ectodomain.37,39,42–44
Here, we applied an in vitro model of isolated primary
cardiac ﬁbroblasts to comprehensively study the effects and
mechanisms of sCD74 and MIF in myocardial ﬁbrosis and
evaluated circulating sCD74 and MIF in plasma samples of
patients suffering from CHD and advanced HF.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure, because of
ongoing studies.
Clinical Perspective
What Is New?
• The effect and molecular mechanisms of the soluble CD74
receptor domain (sCD74) in cardiac ﬁbrosis are still elusive.
• Present ﬁndings demonstrated that sCD74 and macrophage
migration inhibitory factor (MIF) synergistically induce
necroptosis in cardiac myoﬁbroblasts, whereas cardiomy-
ocytes were not prone to sCD74/MIF-induced cell death.
• Preliminary clinical data revealed a lowered sCD74/MIF
ratio in heart failure patients, indicating that sCD74 and MIF
might affect disease progression in patients with heart
failure.
What Are the Clinical Implications?
• This is the ﬁrst study demonstrating that cardiac myoﬁ-
broblast can undergo sCD74/MIF-regulated necroptosis,
which might offer new insights into the mechanism of
myoﬁbroblast depletion during post–myocardial infarction
scar maturation.
• MIF and sCD74 could represent a potential therapeutic
target to modulate cardiac remodeling and disease pro-
gression in heart failure.
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Animals
All animal experiments were performed in accord with the
local institution’s Ethical Review Committee and were
approved by an animal protection representative at the
Institute of Animal Research of the RWTH Aachen University
Hospital in accord with German Animal Protection Law §4,
Section 3. All experimental procedures were approved by the
Animal Care and Use Committee of the local authorities
(TV11311A4, AC, LANUV NRW, Essen, Germany). Primary
cultures of cardiac ﬁbroblasts were generated from the heart
of 1- to 7-day-old wild-type (WT; C57Bl/6J) mice (Charles-
River Laboratories, Sulzfeld, Germany) or CD74 knockout (B6-
(Cd74)tm) mice.45 Mice were fed normal chow diets and
housed under standardized light-dark cycles and speciﬁc
pathogen-free conditions.
Patients
Blood samples were received from patients after informed
consent, approved by the Local Ethic Committee (registration
number: EK 151/09), and registered at clinical trials.gov
(ClinicalTrials.gov Identiﬁer: NCT02488876).
Reagents
All reagents were obtained from Sigma-Aldrich (St. Louis,
MO), Thermo Fisher Scientiﬁc (Schwerte, Germany), or Roth
(Karlsruhe, Germany), if not stated otherwise.
Isolation and Culture of Murine Fibroblasts
Cardiac ﬁbroblasts were isolated from hearts of 1- to 7-day-
old C57BL/6J WT and/or Cd74/ mice. Brieﬂy, hearts were
freed from atria, valves, and vessels, washed in HBSS, and cut
in 2 to 4 pieces. Heart tissue was predigested with 0.05%
trypsin/HBSS solution under gentle rotation at 4°C overnight.
On the next day, predigested tissue was incubated for several
cycles with 250 U/mg of collagenase/HBSS solution at
37°C. The ﬁrst supernatant was discarded, and the following
supernatants were pooled in prechilled centrifuge tubes with
growth medium consisting of low-glucose (0.1%) DMEM, 10%
horse serum, 5% FCS, 100 U/mL of penicillin/streptomycin,
and 20 mmol/L of HEPES. After centrifugation (8 minutes at
500g at room temperature [RT]), the pellet was resuspended
in growth medium and ﬁltered through a prewetted 100-lm
cell strainer (BD Falcon, Durham, NC). Cardiac cells were
preplated for 90 minutes to separate fast-attaching ﬁbrob-
lasts from other cardiac cell types. Fibroblasts were then
detached with trypsin and seeded at 100 000 cells/cm2 in
cell-culture dishes coated with 5 mg/mL of ﬁbronectin in
0.02% gelatin and cultivated for 10 to 14 days at 37°C.
Culture of Murine Cardiomyocytes
HL1 cells were established and provided by Claycomb
Laboratory (Toronto, Ontario, Canada). Because of their
ability to maintain contraction and express phenotypic
characteristics of cardiomyocytes, HL1 cells are a commonly
used cell line for study of cardiac function. Cells were
maintained in Claycomb culture medium supplemented with
10% FCS, 1% penicillin/streptomycin, 0.1 mmol/L of nore-
pinephrine, and 2 mmol/L of L-glutamine and routinely
cultured at 37°C and 5% CO2 in a humidiﬁed incubator. The
Claycomb medium was stored light-protected. To maintain
the phenotypic characteristics and the contracting ability of
HL1 cells, culturing required the supplementation with
0.1 mmol/L of norepinephrine and, most important, FCS
derived from the Batch 11A568, which was pretested by the
Claycomb Laboratory. For experiments, 60 000 cells/cm2
were seeded on ﬁbronectin/gelatin-coated plates 24 hours
before treatment.
Immunoﬂuorescence Staining
Isolated primary cardiac ﬁbroblasts were seeded at
100 000 cells/cm2 in IBIDI dishes (IBIDI, Martinsried, Ger-
many). After 5 hours, 3 days, and 5 days, they were washed
with PBS and ﬁxed with 4% PFA for 20 minutes. Subse-
quently, cells were washed 3 to 5 times with PBS, followed
by 2 hours of blocking (2% BSA in PBS-T) and an overnight
incubation with the primary antibody (1:200 dilution in 2%
BSA in PBS-T) in the dark at 4°C. Fibroblasts were co-
stained with vimentin, a ﬁbroblast marker and a-smooth
muscle actin (a-SMA), a myoﬁbroblast marker. On the next
day, cells were washed 3 to 5 times with PBS and incubated
with the secondary antibody mixture (1:200 dilution in 2%
BSA in PBS-T) in the dark at RT for 2 hours (Table S1).
Following 3 to 5 wash cycles with PBS, cells were covered
with Fluoromount G (SouthernBiotech, Birmingham, AL),
nuclei stained with 40,6-diamidino-2-phenylindole, and,
ﬁnally, sealed with a cover slide. Images were recorded by
Leica DM 2500 (Leica Microsystems, Wetzlar, Germany).
Images were processed using DISKUS (Hilgers, K€onigswinter,
Germany).
Experimental Setup of Cardiac Myoﬁbroblast and
Cardiomyocytes Incubations
Cardiac myoﬁbroblasts were incubated with increasing con-
centrations of sCD74 (0, 0.04, 0.16, 8, 16, and 40 nmol/L;
R&D Systems, Minneapolis, MN) with or without recombinant
MIF (rMIF; 8 nmol/L; PeproTech. Rocky Hill, NJ). Studies in
mouse cardiomyocytes (HL1) as well as signaling and
mechanistic studies in myoﬁbroblasts were then performed
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with the highest sCD74 concentration (40 nmol/L) in the
presence versus absence of rMIF (8 nmol/L). For inhibition
studies, 1 hour before sCD74/rMIF application, ﬁbroblasts
were treated with 12.6 lmol/L of CXCR4 inhibitor AMD3100,
14.2 lmol/L of CXCR2 inhibitor SB225002, or 100 lmol/L
of receptor-interacting serine/threonine-protein kinase 1
(RIP1) inhibitor 7-Cl-O-Nec-1 (necrostatin-1s, Nec1s; Merck
Millipore, Darmstadt, Germany). The experimental setup is
illustrated in Figure S1.
Survival Assays
Cell survival was assessed by trypan blue staining and
counting. Cells were detached with accutase 20 to 24 hours
after stimulation and mixed with the equal volume of 0.4%
trypan blue solution (Bio-Rad, Munich, Germany). The sus-
pension was transferred to counting slides (Bio-Rad), and total
as well as living cell number was analyzed automatically by
using the TC20 Automated Cell Counter (Bio-Rad). Cell
viability was calculated by the ratio of living to total cell
count, and all values were normalized to cell viability of
control cells.
RNA Extraction and Quantitative Real-Time PCR
Total RNA was isolated 8 hours after stimulation using the
Nucleo Spin RNA/Protein kit (Machery-Nagel, D€uren, Ger-
many), and 1 lg of mRNA was reverse-transcribed into
cDNA using a high-capacity cDNA reverse transcription kit
(Applied Biosystems, Carlsbad, CA). mRNA quality and
concentration were measured by the Inﬁnite 200 PRO
(Tecan, M€annedorf, Switzerland). PCR was performed using
50 ng of cDNA and TaqMan probes (Applied Biosystems;
Table S2) on a StepOne Plus Real-Time PCR System (Applied
Biosystems). Glyceraldehyde 3-phosphate dehydrogenase
was used as a housekeeping gene. Relative quantity values
were calculated according to the DDCt method and
normalized to control.
Gene Expression Microarray
Gene expression analysis of cardiac ﬁbroblasts for each
treatment (carrier, rMIF, sCD74, and rMIF/sCD74) was
carried out using the mouse Clariom S Array (Affymetrix,
Santa Clara, CA) in independent triplicates according to the
Minimum Information About a Microarray Experiment
(MIAME) criteria. Total RNA was isolated 8 hours after
stimulation using the Nucleo Spin RNA/Protein kit (Machery-
Nagel) and quantiﬁed (Nanodrop). RNA quality was assessed
using the RNA 6000 Nano Assay with the 2100 Bioanalyzer
(Agilent, Santa Clara, CA). Samples, each 150 ng of total
RNA, for mouse Clariom S Arrays were prepared and
hybridized to the arrays according to the GeneChip WT PLUS
Reagent Kit (Affymetrix), according to the manufacturer’s
protocol. Processed samples were hybridized to mouse
Clariom S Arrays at 45°C for 16 hours with 60 rpms,
washed and stained on a Fluidics Station 450 (program:
FS450 0007), and scanned on a GeneChip Scanner 3000 7G
(both Affymetrix). Raw image data were analyzed with
Affymetrix Expression Console€a Software (Affymetrix); gene
expression intensities were normalized and summarized with
SST-RMA (robust multiarray average algorithm). In order to
identify genes differentially expressed between different
treatments, a class comparison analysis using Affymetrix
Transcriptome Analysis Console (TAC) 2.0 Software was
performed. Differences were considered signiﬁcant if the
2-sided P value was <0.05. To perform pathway over-
representation analysis, data were analyzed with the
software package, AltAnalyze (version 2.0.8), using KEGG
(Kyoto Encyclopedia of Genes and Genomes) as the pathway
database. Over-representation parameters were a Z-score
threshold of 1.96, a Fisher’s exact test P-value threshold of
0.05, and a number of changed genes threshold of 3. Gene
expression was considered as changed if transcript levels
between the different treatment groups were differential
with a ≥1.5-fold change and a raw P<0.05. Microarray data
from this publication have been submitted to the GEO (Gene
Expression Omnibus) repository and are available under
accession number GSE108999.
Western Blotting
To assess kinase activation levels, cell lysates were harvested
at 0.5 and 10 hours after stimulation. Cells were lysed with
19LDS buffer containing 50 mmol/L of DTT. Samples were
soniﬁed to shear genomic DNA, and potential cell debris were
spun down at 4°C at 12 000g for 10 minutes. Afterward,
supernatant was boiled at 95°C for 5 minutes and 100 000
cell equivalents/lane were loaded on a 10% SDS polyacry-
lamide gel (Bio-Rad) for protein separation. Western blotting
and immunodetection as well as reprobing of membranes
were performed according to a previous publication.46 Brieﬂy,
for Western blotting, proteins were transferred onto a PVDF
membrane (Bio-Rad), blocked with 5% BSA or nonfat dry milk
in TBS-T, and probed with primary antibody at 4°C overnight
(Table S1). On the next day, membranes were incubated with
an HRP-conjugated secondary antibody at RT for 2 hours.
Blots were developed with Clarity Western ECL Substrate (Bio-
Rad) or Supersignal West Femto Maximum Sensitivity Sub-
strate, and the resulting chemiluminescence was detected
using the ChemiDoc MP System (Bio-Rad). Band intensities
were analyzed using the Image Lab software (Bio-Rad) and
normalized to unphosphorylated protein. To assess total
protein levels as well as glyceraldehyde 3-phosphate
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dehydrogenase or tubulin, blots were restored with stripping
buffer for 15 minutes at RT, blocked again with 5% BSA or
nonfat dry milk in TBS-T, and incubated with primary antibody
at 4°C overnight followed by secondary antibody incubation
and detection.
ELISA
Soluble mouse tumor necrosis factor alpha (TNFa) concen-
trations in supernatants as well as circulating MIF levels in
plasma samples were quantiﬁed by ELISA according to the
manufacturer’s instructions (R&D Systems). Before analysis,
samples were diluted 1:10 in reaction buffer (1% BSA and
PBS) for the MIF ELISA, whereas samples for the TNFa ELISA
were measured undiluted.
So far, no commercial sCD74 ELISA is available. For
sCD74 ELISA, the anti-CD74 antibody (clone C-16; Santa
Cruz Biotechnology, Heidelberg, Germany) was diluted
1:800 in PBS and incubated (100 lL/well) in a 96-well
ELISA plate at 4°C overnight, followed by washing with PBS-
T. Blocking was performed with 300 lL/well of blocking
buffer solution (1% BSA and PBS) at room temperature for
2 hours, followed by washing with PBS-T. Next, plasma
samples were diluted 1:10 in reaction buffer (1% BSA and
PBS), added (100 lL/well) onto the plate, and incubated
overnight at 4°C, followed by washing. As CD74 protein
standard, we used a Chinese hamster ovary–derived Gln73-
Met232 construct with an N-terminal HA (YPYDVPDYA) tag
(R&D Systems). Anti-CD74 detection antibody (clone LN-2;
Santa Cruz Biotechnology) was added at a 1:500 dilution in
reaction buffer (100 lL/well), and the plate was incubated
for 2 hours at RT, followed by washing with PBS-T.
Immunoglobulin G HRP-linked secondary antibody (Cell
Signaling Technology, Danvers, MA) then was added for
1 hour. Unbound peroxidase was removed by washing
followed by application of substrate solution containing
H2O2 and TMB solution (3,30,5,50-tetramethylbenzidine) at a
ratio of 1:1. Wells were incubated with the substrate for a
maximum of 20 minutes in the dark until a change in color
was visible. The colorimetric reaction was stopped by
adding 1 mol/L of H2SO4. Finally, the assay was read out
and quantiﬁed using a Victor Multilabel Counter at 450 nm.
Ratio of sCD74/MIF was calculated by dividing the molar
serum concentration ratio of circulating CD74 (19.34 kDa)
by MIF (12.5 kDa).
Receptor Expression by Flow Cytometry
Cell-surface expression of the death receptor, TNF receptor
1, Toll like receptors (TLR) 2 and TLR4 as well as MIF
receptors CXCR2, CXCR4, and CD74 on myoﬁbroblasts
were analyzed with ﬂow cytometry at different time points
after stimulation (0.5, 4, and 8 hours). At indicated time
points, ﬁbroblasts were washed with glycine buffer
(50 mmol/L of glycine, 150 mmol/L of NaCl in ddH2O,
pH 2.8) followed by 3 sequential washing steps with PBS.
Afterward, cells were detached by scraping, centrifuged
(500g, 5 minutes, RT) and resuspended in an appropriate
volume of prechilled FACS buffer (PBS [pH 7.2] with 0.5%
BSA and 0.01% sodium azide) to obtain 49106 cells/mL.
For each preparation, 100 000 cells were stained with
antibody listed in Table S3 for 20 minutes in the dark at
4°C. After incubation, cells were washed with 1 mL of FACS
buffer and ﬁnally resuspended in 0.4 mL of FACS buffer to
perform ﬂow cytometry analysis using the FACSCanto II (BD
Biosciences, Heidelberg, Germany). Data were analyzed
using FlowJo software (Version 10.0.7; FlowJo LLC, Ashland,
Oregon).
Statistical Analysis
In this exploratory analysis, after testing for normal distri-
bution (Shapiro–Wilk test), data were statistically analyzed
and graphically displayed using GraphPad PRISM (GraphPad
Software Inc, La Jolla, CA). Data are represented as
meanSEM, if not stated otherwise.47 Given the explora-
tory-driven character of MIF and sCD74 dose experiments
on cell viability as well as signaling studies, normally
distributed data were analyzed using a 2-tailed, unpaired t
test without multiple-test adjustments in order to increase
the power to detect real effects that would be otherwise
compromised.48 Exploratory analysis per se should empha-
size on descriptive analysis graphically or numerically.49 In
contrast, after determination of promising concentrations, all
other experiments were hypothesis-driven and thus tested
for signiﬁcance using a 2-tailed, unpaired t test followed by
Bonferroni correction.48,50 In all cases, P<0.05 was consid-
ered statistically signiﬁcant. Besides statistical signiﬁcant
testing, the magnitude of the effect was evaluated by using
Cohen’s d as an effect size index, and statistical power
calculations were performed using the free software,
G*power 3.1.9.2, provided by the Heinrich-Heine University
D€usseldorf. For preliminary clinical data, the classiﬁcation in
small, medium, and large effects were based on Cohen’s
conventions d=0.2, d=0.5, and d=0.8, respectively. In
contrast to clinical studies, the sample size in in vitro
experiments is very limited and is commonly below n=15,
requiring adaptations of the classiﬁcation. Thus, only large
effects were considered as meaningful effects. Assuming
n=6 as an average number of biological replicates with a
given type I error of a=0.05 and type II error of b=0.20,
d≥1.8 were deﬁned as a large effect size in the experimental
part of our study. The calculated effect size of each
experiment is listed in Table S4.
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Results
Co-Treatment With sCD74 and MIF Triggers Cell
Death in Myoﬁbroblasts but Not in
Cardiomyocytes
We used an in vitro model of primary cardiac ﬁbroblasts,
which rapidly differentiate into myoﬁbroblasts when cultured
on plastic surfaces. A gain of myoﬁbroblast-speciﬁc markers
including a-SMA, collagen 1a1 (Col1a1), and ﬁbronectin 1
(FN1) with an increasing cultivation period, veriﬁed the
activated phenotype of cardiac ﬁbroblasts (Figure 1A and
1B). First, we studied the inﬂuence of increasing concentra-
tions of sCD74 and combinations of sCD74 together with
rMIF on overall myoﬁbroblast viability. Incubation with sCD74
alone reduced the viability of cardiac ﬁbroblasts at concen-
trations ≥8 nmol/L to a small, but signiﬁcant, degree (relative
viability—control versus 40 nmol/L of sCD74: 1001.73%
versus 83.75.99%; P=0.008; d=1.08). Interestingly,
simultaneous treatment with rMIF strongly enhanced the
sCD74-alone effect and substantially elevated the number of
trypan-blue–positive myoﬁbroblasts in a sCD74 dose-depen-
dent manner, with the strongest effect observed at the
highest sCD74/rMIF ratio (8 nmol/L of rMIF versus
40 nmol/L of sCD74/8 nmol/L of rMIF: 98.83.42% versus
47.94.6%; P<0.001, d=3.27; and 40 nmol/L of sCD74
versus 40 nmol/L of sCD74/8 nmol/L of rMIF: 83.75.99%
versus 47.94.6%; P<0.001, d=1.86; Figure 1C). This ﬁnding
suggested that MIF and the soluble CD74 ectodomain act
synergistically to promote death of cardiac myoﬁbroblasts,
representing an antiﬁbrotic property. Besides the cell-death–
inducing properties, we evaluated the de-differentiation
potential of combined sCD74/MIF treatment. However, no
change in mRNA expression of typical myoﬁbroblast-speciﬁc
markers was observed 24 hours after sCD74/MIF treatment,
suggesting that sCD74/MIF is not involved in deactivation of
myoﬁbroblasts (Figure S2). Next, we subjected murine
cardiomyocytes either to a solitary or combined treatment
with 40 nmol/L of sCD74 and 8 nmol/L of rMIF and assessed
cell survival 24 hours later by trypan blue exclusion. In
contrast to myoﬁbroblasts, cardiomyocytes were not prone to
sCD74/MIF-induced cell death (sCD74/MIF in myoﬁbroblasts
versus cardiomyocytes: 47.94.6% versus 93.84.4%;
P<0.001, d=3.14), indicating a myoﬁbroblast-speciﬁc effect
of sCD74/MIF (Figure 1D).
Synergistic sCD74/MIF Effect Involves
Necroptotic but Not Apoptotic Cell Death
Mechanisms
In order to identify mechanisms underlying the synergistic cell-
death–promoting effect of sCD74/MIF co-treatment in myoﬁ-
broblasts, we analyzed cleaved caspase-3 levels as an
indication of apoptosis execution51 using Western blot
methodology. We observed no signiﬁcant changes of cleaved
caspase-3 at 10 hours after stimulation (Figure 2A and 2B),
which has been previously shown to be an appropriate time
window for late caspase activation.52 This indicated that the
effect was mediated by an apoptosis-independent mechanism.
We therefore hypothesized that a necroptotic cell death
mechanism may account for the observed effect. Necroptosis
is a special subtype of programmed necrosis that is mech-
anistically distinct from apoptosis, but may be also triggered
by members of the TNF superfamily, and thus shares some
upstream events with extrinsic apoptosis cascades. Yet,
necroptotic cell death cascades involve inhibition of caspase-
8 activity. The lack of proteolytic activity of caspase-8 allows
autophosphorylation of RIP1 and subsequent RIP3 and mixed
lineage kinase domain-like pseudokinase (MLKL) activation.
Both phospho-RIP3 and phospho-MLKL assemble in so-called
necrosomes to trigger cell death.53 We assessed RIP3 activity
by Western blot 10 hours after incubation with sCD74/rMIF
and observed a 2-fold increase of RIP3 phosphorylation
compared with untreated control (control versus sCD74/
rMIF: 100% versus 222.245.98%; P=0.0376, d=1.88),
whereas neither rMIF nor sCD74 treatment alone affected
phospho-RIP3 levels (Figure 2C and 2D). To conﬁrm that
necroptosis contributes to cell death induction, we blocked
activity of RIP1, the upstream kinase of RIP3, with the
pharmacological inhibitor, 7-Cl-O-Nec1 (Nec1s).54 Surpris-
ingly, Nec1s-pretreated myoﬁbroblasts demonstrated a small,
but signiﬁcant, decrease in cell viability following MIF
treatment compared with control cells (Nec1s/control versus
Nec1s/MIF: 99.723.04% versus 79.624.63%; P=0.025,
d=1.81). However, in accord with our hypothesis, sCD74/
MIF-induced cell death in cardiac ﬁbroblasts was signiﬁcantly
rescued by inhibition of RIP1 kinase activity (DMSO versus
Nec1s: 52.733.84% versus 73.472.57%; P=0.007,
d=2.29), conﬁrming that necroptosis contributes to cell death
triggered by sCD74/MIF (Figure 2E).
TNFa Is Not a Mediator of sCD74/MIF-Induced
Necroptosis
It is well known that gene expression of inﬂammatory
cytokines and soluble factors are induced by MIF and other
stress stimuli. Myoﬁbroblasts have been shown to produce
and secrete TNFa,55 which mediates apoptosis- as well as
necroptosis-dependent cell death pathways.53 To test
whether sCD74/rMIF-triggered cell death is mediated by
TNFa, we determined the mRNA level of TNFa after 8 hours
as well as intra- and extracellular protein levels after
10 hours. Interestingly, neither mRNA nor protein levels of
TNFa were inﬂuenced by the stimulation, independent of
treatment (Figure S5A through S5D; whole blots of
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Figure 1. Co-treatment with sCD74 and MIF promotes cell death in cardiac
myoﬁbroblasts. A, Primary isolated cardiac ﬁbroblasts were co-stained with the
ﬁbroblast marker, vimentin (green), the myoﬁbroblast marker, a-smooth muscle actin
(a-SMA) (red), and nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI; blue)
after 0 (5 hours), 3, and 5 days in culture. Size bar, 200 lm. B, mRNA level of a-SMA,
collagen 1a1 (Col1a1), and ﬁbronectin 1 (FN1) were determined 5 hours (day 0) and
5 days after plating by the RT-qPCR method. Data represent meanSEM of 3
independent experiments and were analyzed with a 2-tailed, unpaired t test.
***P<0.001 vs day 0. C, Cardiac myoﬁbroblasts (MyoFBs) isolated from hearts of
wild-type C57BL/6J (WT) mice were treated with increasing concentrations of sCD74
(0, 0.04, 0.16, 8, 16, and 40 nmol/L) without or with rMIF (8 nmol/L). After 24 hours,
cells were stained with trypan blue and cell numbers were assessed. Data were
analyzed with a 2-tailed, unpaired t test and represent meansSEM of at least 7
independent experiments. *P<0.05; **P<0.01; ***P<0.001 without (w/o) MIF vs with
MIF respectively; §P<0.05; §§P<0.01 vs untreated control respectively; $$P<0.01;
$P<0.001 vsMIF control respectively. D,Murine cardiomyocytes (CMs)were stimulated
with40 nmol/L of sCD74 in the absenceor presence of 8 nmol/L of rMIF for 24 hours,
followed by trypan blue staining. Percentage of survival of CMs was compared with
MyoFBs. Data represent meanSEM of 6 independent experiments and were analyzed
with a 2-tailed, unpaired t test with multiple correction (n=9). $$$P<0.001 vs control of
MyoFBs; **P<0.01 MyoFBs vs CMs. MIF indicates macrophage migration inhibitory
factor; RQ indicates relative quantity; rMIF, recombinant MIF; sCD74, soluble CD74.
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intracellular TNFa and glyceraldehyde 3-phosphate dehydro-
genase are shown in Figure S6).
To ask whether newly synthesized cytokines or other soluble
factors are involved in cell death induction, WT ﬁbroblasts
(“donor cells”) were stimulated with sCD74 or rMIF either alone
or in combination. After 6 and 10 hours, supernatants were
transferred to unstimulated WT ﬁbroblast (“recipient cells”).
Following 20 to 24 hours of incubation, cell viability of donor
and recipient cells was determined. At both time points, donor
cells showed a signiﬁcantly reduced survival after treatment
with sCD74/rMIF comparedwith control, as expected (6 hours:
1003.63% versus 69.905.37%; P<0.001, d=1.76; 10 hours:
1003.13% versus 56.156.67%; P<0.001, d=2.99). In con-
trast, recipient cells showed only a slight decrease in cell
Figure 2. sCD74/MIF-induced death of myoﬁbroblasts is triggered by RIP1/RIP3-dependent necroptosis.
Cardiac wild-type myoﬁbroblasts were treated solitarily or simultaneously with MIF and sCD74, and lysates
were taken at 10 hours. A and B, Cleaved caspase-3 levels (Cl Casp 3) as well as (C and D) relative
phosphorylation levels of receptor-interacting serine/threonine-protein kinase 3 (RIP3) were assessed by
Western blotting and immunostaining. Instead of showing the whole blot, only relevant bands were cut out
and arranged in the right order. Uncut blots are shown in Figures S3 and S4. Data represent meanSEM of
at least 3 independent experiments. Data were analyzed with a 2-tailed, unpaired t test. $P<0.05 vs control.
E, Cardiac wild-type ﬁbroblasts were pretreated with dimethyl sulfoxide (DMSO) or a potent necroptosis
inhibitor (Nec1s) for 1 hour followed by solitary or co-treatment with sCD74 and rMIF. After 20 to 24 hours
of incubation, cell numbers were quantiﬁed by trypan blue staining and automated counting. Data were
analyzed with a 2-tailed, unpaired t test and corrected for multiple comparison (n=9) using Bonferroni’s
posttest. Data represent meanSEM of at least 8 independent experiments for inhibition studies. **P<0.01
DMSO vs Nec1s; §§§P<0.001 vs DMSO control; $P<0.05, $$$P<0.001 vs Nec1s control respectively. GAPDH
indicates glyceraldehyde 3-phosphate dehydrogenase; MIF, macrophage migration inhibitory factor; pRIP3,
phosphorylated RIP3; rMIF, recombinant MIF; sCD74, soluble CD74.
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viability upon stimulation with the transferred supernatant of
sCD74/rMIF-treated cells compared with control (10 hours:
102.223.51% versus 87.722.22%; P=0.032, d=1.75), which
was still a signiﬁcantly higher survival level than in donor cells
(donor versus recipient at 10 hours: 56.156.67% versus
87.722.22%; P=0.0046, d=2.25; Figure S5E and S5F). Taken
together, neither TNFa nor other newly synthesized and
released factors could be identiﬁed as mediators of sCD74/
MIF-induced cell death.
Synergism of sCD74/MIF Upregulates Expression
of Genes Involved in Antimicrobial Defense and
Nuclear Factor Kappa B Signaling
Given that neither TNFa nor other soluble factors seem to
mediate sCD74/MIF-induced necroptosis, a microarray anal-
ysis was performed to shed light on sCD74/MIF-dependent
pathways that might explain the cell death of myoﬁbroblasts.
Following treatment with either sCD74, rMIF, or sCD74/rMIF,
only a relatively low number of genes were at least 1.5-fold
differentially expressed than control (sCD74 versus control: 14
genes; rMIF versus control: 46 genes, sCD74/rMIF versus
control: 55 genes; Table 1). A marginal overlap of regulated
genes of rMIF alone- and sCD74/rMIF-treated cells (9 genes)
indicated that the combined stimulus activates a unique gene
expression proﬁle different from the individual stimuli (Fig-
ure S7A). A graphical illustration of genes that were signiﬁ-
cantly regulated by either sCD74 or rMIF treatment is shown in
Figure S7B and S7C. A detailed analysis of the genes regulated
by sCD74/MIF treatment demonstrated an increased expres-
sion of genes involved in antimicrobial defense mechanisms
(type I interferon [IFN]-induced genes) and nuclear factor kappa
B (NF-jB) signaling pathways (Figure 3A). An over-representa-
tion analysis conﬁrmed an enrichment of several genes found
in pathways related to infectious diseases, NOD-like receptor
signaling and TNF signaling (Table 2). Quantitative reverse
transcription PCR (RT-qPCR) of the >2-fold upregulated genes
conﬁrmed that IFN-induced protein 44 (Iﬁ44; Figure 3B;
control versus sCD74/rMIF: 1.031.53 versus 4.691.03;
P=0.011, d=2.5), immunoresponsive gene 1 (Irg1; Figure 3C;
control versus sCD74/rMIF: 1.000.32 versus 4.410.88;
P=0.022, d=2.11), and C-type lectin domain family 4, member
e (Clec4e; Figure 3D, control versus sCD74/rMIF: 1.180.30
versus 4.100.65; P=0.011, d=2.36), as well as C-C motif
chemokine ligand (Ccl) 2 (Figure S8C; control versus sCD74/
rMIF: 1.130.27 versus 3.180.58; P=0.049, d=1.83) and
Ccl7 (Figure S8D; control versus sCD74/rMIF: 1.060.14
versus 2.700.22; P<0.001, d=3.65) were signiﬁcantly upreg-
ulated in the presence of sCD74/MIF. Increased expression
levels of 20-50 oligoadenylate synthetase-like 2 (Oasl2) and T-
cell-speciﬁc GTPase 2 (Tgtp2) detected in the microarray was
not veriﬁed by the RT-qPCR method (Figure S8A and S8B).
Taken together, our results suggest that sCD74/MIF might act
as a danger-associated molecular pattern–like signal, thereby
activating the host immune response.
Soluble CD74 Diminishes MIF-Mediated Protein
Kinase B Activation
Recently, Assis et al demonstrated that sCD74 neutralizesMIF-
dependent signaling by membrane-bound CD74.37 Therefore,
we investigated whether sCD74/MIF exhibited a different
activation proﬁle of classical MIF-dependent kinases compared
with MIF-mediated activation of membrane CD74. As expected
from previous work,56 we observed early as well as sustained
protein kinase B (AKT) activation following MIF stimulation
(0.5 hours: P<0.001, d=8.31; 10 hours: P=0.0485, d=1.18).
This effect was signiﬁcantly reduced in the presence of sCD74
(Figure 4A through 4D; whole blots of phosphorylated AKT,
total AKT and tubulin are shown in Figure S9 and S10),
suggesting that sCD74 inhibits MIF-mediated AKT signaling
(rMIF versus sCD74/rMIF, 0.5 hours: 198.78.40% versus
136.224.86%; P=0.0197, d=2.23; 10 hours: 157.530.91%
versus 76.9219.4; P=0.0422, d=1.32). Interestingly, at later
time points, combined sCD74/rMIF treatment induced a 2-fold
activation of p38 compared with control (234.4353.52%;
P=0.03, d=1.88; Figure 4E through 4H; whole blots of
phosphorylated p38, total p38 and glyceraldehyde 3-phosphate
dehydrogenase are shown in Figure S11 and S12). No changes
were observed for other mitogen-activated protein kinases
(MAPKs) such as extracellular signal-regulated kinase 1/2
(ERK1/2) and c-Jun N-terminal kinase (JNK; data not shown).
Soluble CD74 Redirects the Proﬁbrotic MIF/
CXCR4 Signal into an Antiﬁbrotic MIF/CD74
Signal
As mentioned before, the dual role of MIF in MI and cardiac
remodeling has been associated with its receptors, CD74
and/or CXCR2. The role of the MIF/CXCR4 axis has not been
studied in this context. To investigate whether the modulating
properties of sCD74 on MIF signaling are based on a modiﬁed
MIF-mediated surface expression pattern of its receptors, we
assessed the surface expression of the MIF receptors as well
as that of the pattern recognition receptors, TLR2 and TLR4,
and the death receptor, TNF receptor 1, in WT versus Cd74-
deﬁcient cardiac myoﬁbroblasts by ﬂow cytometry analysis.
Cd74 deﬁciency did not affect the basal surface expression
proﬁle of CXCR2, CXCR4, TLR2, TLR4, and TNF receptor 1
(Figure S13 and S14). In accord with Schwartz et al,57 we
demonstrated an MIF-induced internalization of the CXCR4
receptor (Figure S15; 4 hours: 0.580.037; P=0.019,
d=4.11), as well as a CD74-dependent CXCR4 internalization
(Figure S15). In contrast, a MIF-triggered internalization of
DOI: 10.1161/JAHA.118.009384 Journal of the American Heart Association 9
sCD74/MIF Triggers Necroptosis in Myoﬁbroblasts Soppert et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on October 23, 2019
Table 1. Fold Changes and P Values of Differentially Regulated Genes Following Treatment With Either sCD74/rMIF, rMIF, or
sCD74
sCD74/rMIF vs Control rMIF vs Control sCD74 vs Control
Gene Symbol FC P Value Gene Symbol FC P Value Gene Symbol FC P Value
Gm20917 2.02 0.0373 Ddb2 1.9 0.0342 Zfp616 2.36 0.0211
Dsg1b 1.9 0.0246 Gm11099 1.82 0.0113 Olfr830 1.67 0.0422
Olfr77 1.72 0.0369 Gjb6 1.69 0.0351 Ceacam14 1.64 0.0416
Akr1c12 1.69 0.0090 Olfr74 1.69 0.0495 Gm10735 1.6 0.0021
LOC105242925 1.69 0.0263 Ceacam13 1.67 0.0342 Serpinb9e 1.53 0.0216
Afm 1.65 0.0072 Sel1 l2 1.66 0.0011 Bpifa5 1.52 0.0254
Cfap53 1.59 0.0351 Tspan1 1.66 0.0122 Mfap2 1.52 0.0400
Pja1 1.58 0.0191 Rs1 1.65 0.0362 Gm13304 1.5 0.0126
Ctsm 1.56 0.0307 LOC102637808 1.63 0.0205 1810064F22Rik 1.5 0.0495
Nrxn3 1.55 0.0075 Pabpc4 l 1.63 0.0420 Kcnj10 1.5 0.0499
Mmp1b 1.55 0.0137 Smr3a 1.63 0.0458 Zscan30 1.5 0.0095
Vmn2r89 1.55 0.0282 Myrip 1.62 0.0180 Olfr1184 1.58 0.0190
Tnnt3 1.53 0.0181 LOC105242925 1.61 0.0328 Vmn2r74 1.71 0.0198
Serpinb13 1.53 0.0416 Srsx 1.6 0.0289 Gm8050 1.81 0.0283
Gjb6 1.52 0.0169 Vmn2r46 1.6 0.0309
Hgd 1.51 0.0335 Vmn1r222 1.55 0.0145
Nfkbia 1.5 0.0077 Gm14151 1.54 0.0074
Scgb2b23-ps 1.5 0.0194 Vmn1r180 1.53 0.0126
Gpr176 1.5 0.0198 Bcl2 l15 1.52 0.0192
Tnip1 1.5 0.0384 Akr1c12 1.5 0.0170
Alg3 1.51 0.0417 Pnmal2 1.5 0.0233
Unc13c 1.52 0.0271 Fga 1.5 0.0040
Ripk2 1.52 0.0312 Ets2 1.5 0.0169
Clmn 1.52 0.0490 Serpina3 g 1.5 0.0336
Serpinf1 1.53 0.0137 Gm5155 1.51 0.0258
Phlda1 1.55 0.0087 Gm8267 1.52 0.0097
Samt2 1.56 0.0030 1700015F17Rik 1.53 0.0028
Ren1 1.59 0.0008 Dnah8 1.53 0.0381
Tdrp 1.59 0.0038 E130114P18Rik 1.54 0.0150
E130114P18Rik 1.59 0.0230 Rhox4f 1.54 0.0461
Adam18 1.59 0.0266 Zc2hc1b 1.55 0.0044
Ptgir 1.6 0.0172 Vmn1r62 1.57 0.0262
Tnfsf18 1.61 0.0164 Vmn1r62 1.57 0.0262
Tpgs1 1.61 0.0367 Slc22a18 1.57 0.0417
Mrpl38 1.63 0.0148 Vmn1r228 1.6 0.0038
Olfr1129 1.64 0.0060 Slco3a1 1.6 0.0193
Eif6 1.64 0.0302 Meiob 1.64 0.0315
Slc7a2 1.65 0.0022 Olfr1129 1.65 0.0099
Gm21907 1.71 0.0218 Mmp13 1.66 0.0245
Continued
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CD74 and CXCR2 was not observed (Figure S15 and S16).
sCD74 did not diminish MIF-mediated internalization of
CXCR4 (Figure S15). TLR2, TLR4, and TNF receptor 1 surface
expression was not affected either by sole or by co-treatment
with rMIF and sCD74 (Figure S16).
Since Heinrichs et al demonstrated, in an experimental
liver disease model, that MIF-mediated CD74 signaling
reduces ﬁbrosis; we examined Cd74/ myoﬁbroblasts and
asked whether endogenous CD74 contributes to the antiﬁ-
brotic properties of the sCD74/rMIF mixture. Cd74 depletion
rescued myoﬁbroblasts against sCD74/MIF-induced necrop-
tosis observed in WT myoﬁbroblasts (sCD74/rMIF, WT versus
Cd74/: 47.944.55 versus 80.546.34%; P<0.001,
d=1.56; Figure 5A and 5B), indicating a contribution of
endogenous CD74 to sCD74/MIF-triggered cell death.
A potential involvement of CXCR2 and CXCR4 in ﬁbroblast
survival was assessed using cardiac myoﬁbroblasts from WT
cells pretreated with either CXCR2 inhibitor SB225002 or
CXCR4 inhibitor AMD3100. Survival rates of WT ﬁbroblasts
pretreated with SB225002 (sCD74/rMIF, WT+DMSO versus
WT+SB225002: 71.62.33% versus 57.467.06%; P>0.05,
d=1.10) and AMD3100 (sCD74/rMIF, WT+ddH2O versus
WT+AMD3100: 53.33.58% versus 41.295.41%; P>0.05,
d=0.96) followed by sCD74/rMIF stimulation did not change
compared with sCD74/rMIF-treated ﬁbroblasts without inhi-
bitor treatment (Figure 5C through 5F), suggesting that activa-
tion of the CXCR2 or CXCR4 receptor is not involved in sCD74/
MIF-induced cell death. In contrast, inhibition of CXCR4 by
AMD3100 before MIF-alone treatment resulted in signiﬁcantly
decreased cell viability (WT+AMD3100, control versus
MIF: 93.953% versus 58.258.33%; P=0.008, d=1.95) that
was comparable to sCD74/rMIF-induced cell death
(WT+AMD3100,MIF versus sCD74/rMIF: 58.258.33% versus
41.295.41%; P=0.56, d=0.86; Figure 5E and 5F). This ﬁnding
suggests that sCD74 inhibits the MIF/CXCR4 axis and thus
diminishes prosurvival signaling (representing a proﬁbrotic
signal) and inhibits CXCR4-mediated counter-regulation of the
CD74 axis, resulting in a CD74-dependent “net” pronecroptotic
signal (ie, antiﬁbrotic signal). Taken together, these results
provide evidence that sCD74 reroutes the MIF/CXCR4-
proﬁbrotic signal in myoﬁbroblasts into a CD74-based antiﬁ-
brotic signal.
Clinical Relevance of sCD74/MIF for the
Development of HF
To investigate the role of sCD74/MIF in the development of HF,
we analyzed sCD74 and MIF concentrations in plasma samples
of healthy volunteers, patients with CHD, and patients with
advanced HF by ELISA. Compared with the healthy cohort, CHD
and HF patients demonstrated a signiﬁcant increase of
circulating MIF (healthy: 561.7194.6 pg/mL; CHD: 2098
231.6 pg/mL; P=0.0017, d=3.35; HF: 47291197 pg/mL;
P=0.0139, d=2.43). Furthermore, the HF cohort had
Table 1. Continued
sCD74/rMIF vs Control rMIF vs Control sCD74 vs Control
Gene Symbol FC P Value Gene Symbol FC P Value Gene Symbol FC P Value
Marco 1.73 0.0110 Hoxa13 1.67 0.0468
Cyp2j12 1.8 0.0300 Vmn1r28 1.71 0.0257
Isg20 1.81 0.0085 Slc7a2 1.78 0.0325
Iigp1 1.81 0.0318 Ddx43 1.79 0.0217
Ltbp2 1.82 0.0081 Ren1 1.88 0.0059
Pydc3 1.85 0.0472 Ifi44 1.94 0.0419
Birc3 1.87 0.0166 Gm11096 30.61 0.0002
Mapk11 2.06 0.0351
Slco3a1 2.08 0.0108
Ccl7 2.19 0.0005
Oasl2 2.73 0.0316
Ccl2 2.9 0.0191
Tgtp2 3.12 0.0223
Clec4e 3.82 0.0234
Irg1 4.77 0.0073
Ifi44 5.22 0.0203
FC indicates fold change; rMIF, recombinant macrophage migration inhibitory factor; sCD74, soluble CD74.
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signiﬁcantly elevated MIF levels compared with CHD
(P=0.0456, d=1.52; Figure 6A). In contrast, levels of circulating
sCD74 did not differ between cohorts (Figure 6B). Calculation
of the molar ratio of sCD74/MIF revealed a 6- and 10-fold
decrease in CHD and HF patients, respectively, compared with
healthy controls (healthy versus HF: 17.4710.09 versus
Figure 3. Treatment with sCD74/MIF signiﬁcantly upregulates gene expression of type I interferon (IFN)-
induced genes. WT were treated with 40 nmol/L of sCD74 in the absence or presence of 8 nmol/L of rMIF.
After 8 hours, mRNA was isolated. A, Microarray analysis was performed, and only genes that were at least
1.5-fold differentially regulated upon sCD74/rMIF treatment compared with control were depicted.
Independent triplicates were performed. Corresponding P values are depicted in Table 1. The 9 genes that
were also signiﬁcantly regulated upon MIF-treatment were marked as overlap. Type I IFN-induced genes and
genes involved in NF-jB signaling pathways are indicated as black and dark gray bars, respectively. Genes
labeled as gray bars seem not to contribute to specialized function and pathways. B and D, RT-qPCR was
performed with the cDNA and Taqman probes speciﬁc for the type I IFN-induced genes, interferon-induced
protein 44 (Iﬁ44), immunoresponsive gene 1 (Irg1), and C-type lectin domain family 4, member e (Clec4e).
GAPDH was used as a housekeeping gene. Relative quantity (RQ) values were calculated according to the
DDCt method and normalized to control. Data represent meanSEM of at least 4 independent experiments
and were analyzed with a 2-tailed, unpaired t test with multiple correction (n=5). $P<0.05 vs control;
*P<0.05 vs rMIF. GAPDH indicates glyceraldehyde 3-phosphate dehydrogenase; IFN, interferon; MIF,
macrophage migration inhibitory factor; NF-jB, nuclear factor kappa B; rMIF, recombinant MIF; sCD74,
soluble CD74; WT, wild type.
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1.410.62; P=0.163, d=1.12; healthy versus CHD:
17.4710.09 versus 2.861.20; P=0.147, d=1.02; Fig-
ure 6C). Because of the limited cohort size, these differences
did not reach signiﬁcance. Effect size and statistical power
calculations demonstrated that the preliminary clinical data
lack statistical power (healthy versus CHD: 1-b=0.2588;
healthy versus HF: 1-b=0.2687; CHD versus HF: 1-b=0.1449)
attributed to small sample sizes. This might explain why the
statistical signiﬁcant test failed to detect a meaningful or
obvious effect (P>0.05) either between the diseased cohorts
versus healthy subjects or between CHD versus HF patients,
despite a large effect size of the sCD74/MIF ratio between
healthy cohorts versus CHD and HF patients (healthy versus
CHD: d=1.02 and healthy versus HF: d=1.12) and a medium
effect between CHD versus HF subjects (CHD versus HF:
d=0.69) were demonstrated. Thus, an adequately powered
study with at least 35 patients per group is needed. Together,
the ﬁndings nevertheless suggest that low sCD74
Table 2. Enrichment Analysis of sCD74/MIF-Regulated Genes
Database ID Pathway Description C Regulated Genes R P Value
KEGG mmu04060 Cytokine-cytokine receptor interaction 264 Ccl2 (2.90); 4.0 0.0369
Ccl7 (2.19);
Tnfsf18 (1.61)
KEGG mmu04062 Chemokine signaling pathway 196 Nfkbia (1.5); 5.4 0.0170
Ccl2 (2.90);
Ccl7 (2.19)
KEGG mmu05152 Tuberculosis 178 Mapk11 (2.06); 6.0 0.0131
Ripk2 (1.52);
Clec4e (3.82)
KEGG mmu05164 Influenza A 170 Nfkbia (1.5); 6.2 0.0116
Mapk11 (2.06);
Ccl2 (2.90)
KEGG mmu04722 Neurotrophin signaling pathway 123 Nfkbia (1.5); 8.6 0.0048
Mapk11 (2.06);
Ripk2 (1.52)
KEGG mmu05145 Toxoplasmosis 113 Birc3 (1.87); 9.4 0.0038
Nfkbia (1.5);
Mapk11 (2.06)
KEGG mmu05142 Chagas disease (American
trypanosomiasis)
103 Nfkbia (1.5); 10.3 0.0029
Mapk11 (2.06);
Ccl2 (2.90)
KEGG mmu04621 NOD-like receptor signaling pathway 169 Birc3 (1.87); 10.5 <0.0001
Nfkbia (1.5);
Mapk11 (2.06);
Ripk2 (1.52);
Ccl2 (2.90)
KEGG mmu04668 TNF signaling pathway 109 Birc3 (1.87); 13.0 0.0002
Nfkbia (1.5);
Mapk11 (2.06);
Ccl2 (2.90)
Birc3 indicates baculoviral IAP repeat-containing 3, alternative name, cellular inhibitor of apoptosis 2 (cIAP2); C, Total genes regulated in a certain pathway; Ccl, chemokine (C-C motif)
ligand; Clec4e, C-type lectin domain family 4, member e; FC, fold change; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK11, mitogen-activated protein kinase 11, alternative
name, p38 beta; MIF, macrophage migration inhibitory factor; sCD74, soluble CD74; Nfkbia, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha, alternative
name, I-kappa-B-alpha (IjBa); R, enrichment factor; Ripk2, receptor-interacting serine-threonine kinase 2; sCD74, soluble CD74 receptor ectodomain; Tnfsf18, tumor necrosis factor
(ligand) superfamily, member 18.
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concentrations and high circulating MIF levels may affect
disease progression.
Discussion
MI is frequently associated with the development of HF
because of pathological myocardial remodeling leading to
stiffness of the cardiac muscle and worsening of cardiac
performance.58 As key regulators of ECM turnover and the
major site of collagen and MMP synthesis, myoﬁbroblasts are
presumed to be an attractive therapeutic target to minimize
the expansion of ﬁbrotic tissue.9 However, in order to develop
and optimize an approach for improving recovery after MI
while avoiding adverse cardiac remodeling, a detailed under-
standing of the complex regulation and interaction of myoﬁ-
broblasts with cytokines and ECM components is mandatory.
Figure 4. sCD74 changes the kinase activation proﬁle of MIF. Following stimulation of WT myoﬁbroblasts,
lysates were taken after 0.5 and 10 hours. Phosphorylation and total protein levels were assessed by
Western blotting, band intensities were densitometric analyzed, and relative activation levels were
normalized to control. Phosphorylation levels of AKT at (A and C) 0.5 and (B and D) 10 hours as well as the
mitogen-activated protein kinase p38 at (E and G) 0.5 and (F and H) 10 hours were determined.
Densitometric analysis of immunostainings as well as representative blots are shown. Instead of showing
the whole blot, relevant bands were cut out and arranged in the respective order. Uncut blots are shown in
Figures S9 through 12. Data represent meanSEM of at least 4 independent experiments. Data were
analyzed with a 2-tailed, unpaired t test. $P<0.05, $$$P<0.001 vs control, respectively; *P<0.05 vs rMIF.
AKT indicates protein kinase B; MIF, macrophage migration inhibitory factor; pAKT, phosphorylated AKT;
pp38, phosphorylated p38; rMIF, recombinant MIF; sCD74, soluble CD74; WT, wild type.
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Previous studies demonstrated that following MI, MIF is
immediately released from injured cardiomyocytes, providing
predominately protective properties through its receptor,
CD74, and its antioxidant capacity.27,59,60 In contrast, a
second delayed wave of MIF derived from inﬁltrating immune
cells contributes to aggravation of cardiac function and
adverse cardiac remodeling, presumably mainly through
CXCR2 and CXCR4.59 The recently discovered soluble CD74
ectodomain (sCD74) fragment expands the understanding
about the complex interaction within the MIF protein family
and necessitates to understand its role within the MIF/
receptor network. The present study identiﬁed an antiﬁbrotic
role of combined treatment with sCD74 and MIF, that is,
“sCD74/MIF,” mainly by inducing programmed cell death in
myoﬁbroblasts. We are the ﬁrst to demonstrate that syner-
gism of MIF and sCD74 induces RIP-dependent necroptosis in
myoﬁbroblasts by promoting a molecular switch from a MIF/
CXCR4-proﬁbrotic signal into a CD74-based antiﬁbrotic signal
(Figure 7). Given that myoﬁbroblast activity is prominently
controlled by cytokines, we hypothesized that the pleiotropic
cytokine, MIF, and the soluble form of its receptor, CD74,
might affect viability and activation of myoﬁbroblasts, thereby
inﬂuencing progression of ﬁbrosis. In fact, we found that
simultaneous, combined, treatment, but not individual stim-
ulation, of myoﬁbroblasts with recombinant MIF and sCD74
triggered a signiﬁcant induction of myoﬁbroblast death. In
contrast, neither the myoﬁbroblastic phenotype nor the
survival of cardiomyocytes were negatively affected. The
Figure 5. sCD74 redirects the MIF/CXCR4-proﬁbrotic signal into a CD74-mediated antiﬁbrotic signal. First, cardiac WT ﬁbroblasts were
treated with CXCR2-inhibitor SB225002, CXCR4-inhibitor AMD3100, or appropriate vehicle controls for 1 hour. Subsequently, (A) Cd74/
cells, (B) wild-type (WT) cells, (D) SB225002-, and (E) DMSO-pretreated myoﬁbroblasts as well as (G) AMD3100- and (H) ddH2O-pretreated WT
myoﬁbroblasts were subjected to 40 nmol/L of sCD74 either alone or together with 8 nmol/L of MIF. Cell numbers were quantiﬁed by trypan
blue staining and automated counting and normalized to untreated control. (C, F, and I) For comparison, data from Cd74/, CXCR2, and CXCR4
inhibition studies were overlaid with their appropriate vehicle control. Data represent meanSEM of at least (A) 14, (B) 12, (D) 6, (E) 6, (G) 6, and
(H) 6 independent experiments. Data were analyzed with a 2-tailed, unpaired t test and corrected for multiple comparison (A, B, D, E, G, and H:
n=5; C, F, and I: n=4) using Bonferroni’s posttest. $$P<0.01, $$$P<0.001 vs control within group respectively; *P<0.05, **P<0.01, ***P<0.001
vs MIF or sCD74 respectively; §§P<0.01, §§§P<0.001 comparison between WT and deﬁcient or inhibited myoﬁbroblasts respectively. CXCR, C-X-
C chemokine receptor; DMSO, dimethyl sulfoxide; MIF, macrophage migration inhibitory factor; rMIF, recombinant MIF; sCD74, soluble CD74;
WT, wild type.
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cell-type–speciﬁc death effect triggered by sCD74/MIF co-
treatment is in accord with previous studies that reported that
the same stimuli or pathways can induce opposing effects in
cardiomyocytes and ﬁbroblasts.61,62 That sCD74/MIF co-
treatment does not induce de-differentiation of myoﬁbroblasts
supports our assumption that it is unlikely that sCD74/MIF-
activated downstream pathways simultaneously affect the
death and de-differentiation of myoﬁbroblasts. However, our
assumption cannot be supported by previous literature
because of a lack of studies that have interrogated the de-
differentiation of cardiac myoﬁbroblast. Taken together, our
results indicate that sCD74/MIF-induced cell death seems to
be a myoﬁbroblast-speciﬁc effect, suggesting that sCD74/
MIF might represent a promising target to regulate the cardiac
remodeling post-MI and disease progression in patients with
HF. During the healing phase, the ECM is cross-linked and
depleted from most cellular components, such as vascular
cells and myoﬁbroblasts, resulting in a mature scar.63 The
understanding of the regulation of myoﬁbroblast death during
wound healing and the discovery of an “off-switch” to rapidly
remove myoﬁbroblasts in a controlled manner would repre-
sent a therapeutic chance. However, the mechanisms that
induce activation of regulated cell death in myoﬁbroblasts are
poorly understood. Although induction of apoptosis-depen-
dent mechanisms has been repeatedly demonstrated as a
trigger of myoﬁbroblast death,63,64 we are the ﬁrst to
demonstrate an activation of a caspase-3–independent (ie,
apoptosis-independent) death pathway in myoﬁbroblasts. We
found that myoﬁbroblasts undergo necroptosis in a RIP1/
RIP3-dependent manner, which is consistent with previous
studies demonstrating that activation of RIP1 and RIP3 are
key pathway elements of necroptosis.65,66 Thus, our ﬁndings
are relevant because they extend the understanding about the
regulation of myoﬁbroblast death.
It has been shown that necroptosis is induced by ligand
binding to TNF family death domain receptors, pattern
recognition receptors, or virus sensors.53 Yet, our data
suggest that neither TNFa nor other soluble factors are
involved in sCD74/MIF-induced necroptosis of cardiac myoﬁ-
broblasts. Interestingly, McComb et al revealed that type I IFN
(IFN-I) signaling is a predominant mechanism of necroptosis in
macrophages treated with LPS.67 In line with these results,
our microarray and RT-qPCR analysis revealed an upregulation
of type 1 IFN-regulated genes in myoﬁbroblasts following
sCD74/MIF co-treatment, suggesting a potential contribution
of type I IFN (IFN-I) signaling to sCD74/MIF-induced necrop-
tosis. Furthermore, an over-representation analysis revealed
enrichment of several genes in pathways of infectious
diseases such as Tuberculosis, Inﬂuenza A, Toxoplasmosis,
and Chagas disease. Thus, sCD74/MIF seems to be recog-
nized in a danger-associated molecular pattern–like manner
to activate components typical for the antimicrobial defense
system.
In accord with previous studies demonstrating an attenu-
ating effect of sCD74 on MIF-triggered signaling,28,37 we
identiﬁed sCD74 as an inhibitor of MIF-mediated AKT
activation. MIF-induced phosphorylation of AKT has previously
been demonstrated to depend on CXCR4 and CD74.57,68
Unlike other G-protein-coupled receptors that rapidly inter-
nalize following stimulation to terminate signaling,69 CXCR4
exhibits a prolonged stimulatory capacity attributed to
endosomal signaling. Recruitment of signaling complexes,
which can include both inhibitors or activators of signaling, to
endosomes determines the signal type.70 Given that the
presence of sCD74 did not inhibit MIF-induced internalization
of either CXCR2 or CXCR4, sCD74 might diminish MIF-
mediated endosomal signaling.69 This mechanistic possibility
needs to be further investigated in future studies.
Figure 6. Circulating CD74 and MIF concentrations in healthy, CHD, and HF patients. Using an ELISA technique, we analyzed (A) MIF and
(B) sCD74 concentrations in plasma samples of healthy volunteers (n=4), patients with coronary heart disease (CHD; n=5), and patients with
advanced heart failure (HF; n=4). C, Ratio of CD74/MIF was calculated by dividing the molar serum concentration of circulating CD74
(19.4 kDa) by MIF (12.5 kDa). Data were analyzed with a 2-tailed, unpaired t test without multiple correction and represent meanSEM.
*P<0.05 vs CHD cohort; $P<0.05, $$P<0.01 vs healthy cohort, respectively. MIF indicates macrophage migration inhibitory factor; sCD74,
soluble CD74.
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This study is the ﬁrst to demonstrate that necroptosis is
dependent on endogenous CD74. However, our study also
indicates that sCD74 inhibits the MIF/CXCR4 axis and thus
induces a molecular switch from MIF-mediated prosurvival
signaling through CXCR4/AKT (proﬁbrotic) to cell death
induction by CD74 (antiﬁbrotic). Our ﬁndings are consistent
with previous studies showing that CD74 mediates antiﬁbrotic
properties whereas CXCR4 promotes proﬁbrotic effects.26,71
Figure 7 illustrates a proposed model by which combined
sCD74/MIF treatment may modulate the survival of myoﬁ-
broblasts.
In addition to these mechanistic ﬁndings, we offer ﬁrst
clinical data from a cohort of patients suffering from CHD and
advanced HF compared with healthy volunteers. These data
provide ﬁrst evidence that low sCD74 concentrations and high
circulating MIF levels might affect disease progression. This
conclusion is supported by a recent clinical study
demonstrating that low levels of the circulating receptor for
advanced glycation end products ectodomain were associated
with increased risk of HF.72 In contrast, overexpression of a
syndecan-4 ectodomain preceding MI induction augmented
the incidence of cardiac rupture and impaired heart function,
apparently attributed to impaired granulation tissue formation
and reduced myoﬁbroblast numbers.73 However, a synergistic
effect of a soluble receptor ectodomain moiety and its ligand
triggering cell death has not been described yet. Taken
together, we suggest that a high sCD74/MIF ratio in the
early/acute phase of post-MI remodeling (“reparative phase”)
would reduce the healing capacity by affecting myoﬁbroblast
number and ECM production negatively. In contrast, in the
late/chronic phase of post-MI remodeling (after-healing
phase), an increased sCD74/MIF ratio would enhance
myoﬁbroblast depletion from the infarct scar, attenuating
reactive ﬁbrosis.
Figure 7. Proposed model of molecular switch between the proﬁbrotic MIF/CXCR4 signal and antiﬁbrotic
MIF/CD74 signal. Recombinant MIF triggers CXCR4 internalization, which requires the presence of CD74.
Subsequently, MIF/CXCR4 axis mediates survival by AKT activation. Although sCD74/MIF still induces
CXCR4 (and CXCR2) internalization, AKT signaling is disturbed. However, the CXCR4/AKT axis seems to be
important to suppress cell death. As soon as MIF-mediated CXCR4 activation is inhibited, signaling by CD74
predominates resulting in RIP1 and RIP3 phosphorylation and, ﬁnally, necroptosis. Furthermore, sCD74/
MIF seems to be recognized in a DAMP-like manner to activate components typical for the antimicrobial
defense system, such as type 1 interferon (IFN)-induced genes. AKT indicates protein kinase B; CXCR, C-X-C
chemokine receptor; DAMP, danger-associated molecular pattern; MIF, macrophage migration inhibitory
factor; RIP1/3, receptor-interacting serine/threonine-protein kinases 1 and 3; rMIF, recombinant MIF;
sCD74, soluble CD74.
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Limitations
We acknowledge that our study has several limitations. First,
the pathological mechanisms of cardiac remodeling and HF
are highly complex and involve ﬁbrosis, inﬂammation, car-
diomyocyte hypertrophy, and apoptosis. We mainly focused
on ﬁbrosis and used a simplistic in vitro model of cardiac
myoﬁbroblasts to investigate the biological function of
combined sCD74/MIF treatment in myocardial remodeling.
Nevertheless, we suggest that our ﬁndings are relevant
because they extend the understanding about the regulation
of myoﬁbroblast death, in which necroptosis has never been
reported before. Additionally, the cell-type–speciﬁc induction
of death in cardiac myoﬁbroblasts by sCD74/MIF and ﬁrst
clinical results indicate that the sCD74/MIF molecular pair
might represent a promising target to regulate the cardiac
remodeling post-MI and disease progression in patients with
HF.
Second, the results of the studies have to be considered as
purely hypothesis-generating and need further conﬁrmation.
On the one hand, the sample size of some in vitro
experiments should be increased especially in experiments
that demonstrated large effects, but reached no statistical
signiﬁcance to avoid negation or underestimation of effects,
which would lead to misinterpretation or wrong conclusions of
underlying mechanisms. Most importantly, on the other hand,
the new hypotheses have to be conﬁrmed in comprehensive
in vivo models. Yet, ﬁrst clinical data support the evidence for
the inﬂuence of sCD74/MIF in the disease progression of HF.
Third, we acknowledge that cardiac ﬁbroblasts were
isolated from hearts of neonatal mice. Yet, previous studies
repeatedly demonstrated the reliability of using a model of
neonatal ﬁbroblasts, which provides comparable results to a
model with adult ﬁbroblasts.74,75 Notwithstanding, this is the
ﬁrst study addressing the molecular mechanisms of action of
sCD74 and MIF in cardiac ﬁbrosis.
Fourth, the preliminary clinical evidence should be cau-
tiously considered within the limits of an exploratory analysis.
An additional adequately powered clinical trial with at least 35
patients per group is certainly needed to further conﬁrm the
ﬁndings. Nevertheless, the present study offers ﬁrst evidence
on the clinical signiﬁcance of MIF and sCD74 and its
synergistic action in cardiac and HF patients.
Conclusion
In summary, our study provides ﬁrst evidence about an
antiﬁbrotic role of sCD74/MIF by inducing necroptosis in a
myoﬁbroblast-speciﬁc manner. Mechanistically, we demon-
strated that sCD74 inhibits the MIF-mediated survival path-
way through the CXCR4/AKT axis, enabling for activation of
necroptosis in a CD74/RIP3-dependent manner. If conﬁrmed
in further clinical cohorts, sCD74/MIF-induced effects may
represent a promising target to regulate disease progression
in patients with HF.
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Table S1. Antibody list used for Western blotting and immunofluorescence staining.  
Antibody Add on Use/ 
Dilution 
Blocking/ 
Dilution 
buffer 
Source MW 
[kDa] 
Manufacturer 
Anti-Actin 1A4 IF 
1:200 
PBS-T   Santa Cruz 
Anti-α-
Tubulin 
 WB 
1:1000 
1% BSA 
In TBS-T 
Mouse 50 Sigma Aldrich, 
Munich, 
Germany 
Anti-AKT  WB 
1:1000 
5% BSA 
in TBS-T 
Rabbit 60 Cell Signaling 
Technology 
Danvers, MA, 
USA 
Anti-
Caspase-3 
 WB 
1:1000 
5% NFDM 
in TBS-T 
Rabbit 17, 19, 
35 
Cell Signaling 
Technology, 
Beverly, MA, 
USA 
Anti-GAPDH D16H11 WB 
1:1000 
5% BSA 
in TBS-T 
Rabbit 37 Cell Signaling 
Technology 
Danvers, MA, 
USA 
Anti-p38  WB 
1:1000 
5% BSA 
in TBS-T 
Rabbit 43 Cell Signaling 
Technology 
Danvers, MA, 
USA 
Anti-RIP3  WB 
1:1000 
5% BSA 
in TBS-T 
Rabbit 53 BioRAD, 
Munich, 
Germany 
Anti-TNF 
alpha 
 WB 
1:700 
3% NFDM 
in TBS-T 
Rabbit 25 Abcam, 
Cambridge, UK 
Anti-
phospho-AKT 
Ser473 WB 
1:1000 
5% BSA 
in TBS-T 
Rabbit 60 Cell Signaling 
Technology 
Danvers, MA, 
USA 
Anti-
phospho-p38 
Thr180/ 
Tyr182 
WB 
1:1000 
5% BSA 
in TBS-T 
Rabbit 43 Cell Signaling 
Technology 
Danvers, MA, 
USA 
Anti-phospho 
RIP3 
Ser232 WB 
1:1000 
5% NFDM 
in TBS-T 
Rabbit 53 Abcam, 
Cambridge, UK 
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Anti-Vimentin  IF 
1:200 
2% BSA  
in PBS-T 
Rabbit 57 Thermo Fisher 
Scientific, 
Waltham, MA, 
USA  
Anti-Mouse HRP WB 
1:5,000 
1% BSA 
in TBS-T 
Donkey  Abcam, 
Cambridge, UK 
Anti-Rabbit HRP WB 
1:10,000 
1% BSA 
in TBS-T 
Donkey  GE Healthcare, 
Munich, 
Germany 
Anti-Mouse 
IgG 
DyLight 
550 
IF 
1:200 
PBS-T Goat  Thermo Fisher 
Scientific, 
Waltham, MA, 
USA 
Anti-Rabbit 
IgG (H+L) 
DyLight 
288 
IF 
1:200 
PBS-T   Thermo Fisher 
Scientific, 
Waltham, MA, 
USA 
 
BSA, bovine serum albumin; HRP, horse radish peroxidase; IF, Immunofluorescence; MW, 
molecular weight NFDM, non-fat dry milk; PBS-T , phosphate-buffered saline with Tween20; 
TBS-T, Tris-buffered saline with 0.1% Tween20; WB, Western blot 
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Table S2. Gene expression analysis using TaqMan assays from Applied Biosystems.  
Gene/TaqMan probe Assay ID 
Acta2 Mm00725412_s1 
FN1 Mm01256744_m1 
Ccl2 Mm00441242_m1 
Ccl7 Mm00443113_m1 
Clec4e Mm01183703_m1 
Col1a1 Mm00801666_g1 
GAPDH Mm99999915_g1 
Ifi44 Mm00505670_m1 
Irg1 Mm01224532_m1 
Oasl2 Mm01201449_m1 
Tgtp2 Mm00786926_s1 
TNFα Mm00443258_m1 
 
Acta2; actin, alpha 2, smooth muscle, aorta (alias: α-SMA); FN1, fibronectin 1; Ccl, C-C motif 
chemokine ligand; Clec4e, C-type lectin domain family 4 member e; Col1a1, collagen, type I, 
alpha 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Ifi44, interferon-induced 
protein 44; Irg1, immunoresponsive gene 1; Oasl2, 2’-5’ oligoadenylate synthetase-like 2; 
Tgtp2, T cell specific GTPase 2; TNFα, tumor necrosis factor α.  
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Table S3. Antibody list used for flow cytometry analysis. 
Antibody Labeling Host Volume Manufacturer 
Anti-mouse-CD74 FITC Rat 3 µl BD Bioscience, 
Heidelberg, Germany 
Anti-mouse-CXCR2 PE Rat 3 µl R&D, Minneapolis, MN, 
USA 
Anti-mouse-CXCR4 FITC Rat 3 µl R&D, Minneapolis, MN, 
USA 
Anti-mouse-TLR2 FITC Rat 3 µl R&D, Minneapolis, MN, 
USA 
Anti-mouse-TLR4 PE Rat 3 µl R&D, Minneapolis, MN, 
USA 
Anti-mouse-TNFRI FITC Hamster 1 µl Abcam, Cambridge, UK  
Anti-hamster IgG FITC Hamster 0.2 µl Abcam, Cambridge, UK 
Anti-rat-IgG2B FITC Rat 3 µl BD Bioscience, 
Heidelberg, Germany 
Anti-rat IgG2A PE Rat 3 µl R&D, Minneapolis, MN, 
USA 
Anti-rat Ig2B FITC Rat 3 µl R&D, Minneapolis, MN, 
USA 
 
FITC, Fluorescein isothiocyanate; PE, Phycoerythrin 
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Table S4. Effect Size. 
    Comparison d (Effect Size) 
Figure 1B 
α-SMA Day0 vs. Day5 16.65 
Col1a1 Day0 vs. Day5 7.44 
Fibronectin 1 Day0 vs. Day5 1.61 
Figure 1C 
Ctrl vs.  
sCD74 treatment alone 
Ctrl vs. 0.04 nmol/L sCD74 0.21 
Ctrl vs. 0.16 nmol/L sCD74 0.51 
Ctrl vs. 8 nmol/L sCD74 1.02 
Ctrl vs. 16 nmol/L sCD74 1.05 
Ctrl vs. 40 nmol/L sCD74 1.05 
MIF vs.  
sCD74/MIF Cotreatment 
MIF vs. 0.04 nmol/L sCD74 + 
MIF 
0.92 
MIF vs. 0.16 nmol/L sCD74 + 
MIF 
1.11 
MIF vs. 8 nmol/L sCD74 + MIF 2.33 
MIF vs. 16 nmol/L sCD74 + MIF 3.30 
MIF vs. 40 nmol/L sCD74 + MIF 3.27 
sCD74 treatment vs.  
sCD74/MIF cotreatment 
0nmol/L sCD74 (Control)  vs.  
0.04 nmol/L sCD74 + MIF 
0.11 
0.04 nmol/L sCD74  vs.  
0.04 nmol/L sCD74 + MIF 
0.91 
0.16 nmol/L sCD74 vs.  
0.16 nmol/L sCD74 + MIF 
1.52 
 8 nmol/L sCD74 vs.  
8 nmol/L sCD74 + MIF 
1.16 
16 nmol/L sCD74 vs.  
16 nmol/L sCD74 + MIF 
3.27 
40 nmol/L sCD74 vs.  
40 nmol/L sCD74 + MIF 
1.86 
Figure 1D 
Effects within CMs 
Ctrl vs. MIF 0.18 
Ctrl vs. sCD74 0.44 
Ctrl vs. sCD74/MIF 0.81 
MIF vs. sCD74/MIF 0.66 
sCD74 vs. sCD74/MIF 0.04 
Effects in CMs vs. MyoFBs 
Control 0.00 
MIF 0.05 
sCD74 0.55 
sCD74/MIF 3.14 
Figure 2A 
Cleaved Caspase 3 level at 
10h 
Ctrl vs. MIF 0.63 
Ctrl vs. sCD74 3.05 
Ctrl vs. sCD74/MIF 0.53 
MIF vs. sCD74/MIF 0.07 
sCD74 vs. sCD74/MIF 0.21 
Figure 2C 
Phosphorylated RIP3 level at 
10h 
Ctrl vs. MIF 2.34 
Ctrl vs. sCD74 0.51 
Ctrl vs. sCD74/MIF 1.88 
MIF vs. sCD74/MIF 1.52 
sCD74 vs. sCD74/MIF 1.73 
Figure 2E Ctrl vs. MIF 0.29 
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Effects within the DMSO  
group 
Ctrl vs. sCD74 0.42 
Ctrl vs. sCD74/MIF 3.50 
MIF vs. sCD74/MIF 2.72 
sCD74 vs. sCD74/MIF 3.83 
Effects within the Nec1s  
group 
Ctrl vs. MIF 1.81 
Ctrl vs. sCD74 1.38 
Ctrl vs. sCD74/MIF 3.39 
MIF vs. sCD74/MIF 0.59 
sCD74 vs. sCD74/MIF 1.56 
Effects in DMSO vs. Nec1s 
group 
Control 0.02 
MIF 0.94 
sCD74 0.72 
sCD74/MIF 2.29 
Figure 3B Ifi44 mRNA 
Ctrl vs. MIF 1.20 
Ctrl vs. sCD74 2.01 
Ctrl vs. sCD74/MIF 2.50 
MIF vs. sCD74/MIF 2.11 
sCD74 vs. sCD74/MIF 1.01 
Figure 3C Irg1 mRNA 
Ctrl vs. MIF 1.26 
Ctrl vs. sCD74 1.36 
Ctrl vs. sCD74/MIF 2.11 
MIF vs. sCD74/MIF 0.69 
sCD74 vs. sCD74/MIF 1.10 
Figure 3D Clec4e mRNA 
Ctrl vs. MIF 0.96 
Ctrl vs. sCD74 0.99 
Ctrl vs. sCD74/MIF 2.36 
MIF vs. sCD74/MIF 0.86 
sCD74 vs. sCD74/MIF 1.59 
Figure 4A 
Phosphorylated AKT level at 
0.5h 
Ctrl vs. MIF 8.31 
Ctrl vs. sCD74 2.21 
Ctrl vs. sCD74/MIF 0.58 
MIF vs. sCD74/MIF 2.23 
sCD74 vs. sCD74/MIF 0.45 
Figure 4B 
Phosphorylated AKT level at 
10h 
Ctrl vs. MIF 1.18 
Ctrl vs. sCD74 0.95 
Ctrl vs. sCD74/MIF 0.64 
MIF vs. sCD74/MIF 1.32 
sCD74 vs. sCD74/MIF 1.02 
Figure 4E 
Phosphorylated p38 level at 
0.5h 
Ctrl vs. MIF 0.14 
Ctrl vs. sCD74 0.20 
Ctrl vs. sCD74/MIF 0.09 
MIF vs. sCD74/MIF 0.16 
sCD74 vs. sCD74/MIF 0.03 
Figure 4F 
Phosphorylated p38 level at 
10h 
Ctrl vs. MIF 2.34 
Ctrl vs. sCD74 0.51 
Ctrl vs. sCD74/MIF 1.88 
MIF vs. sCD74/MIF 1.52 
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sCD74 vs. sCD74/MIF 1.73 
Figure 5A 
Effect of sCD74/MIF on Cd74-
/- 
Ctrl vs. MIF 0.43 
Ctrl vs. sCD74 0.12 
Ctrl vs. sCD74/MIF 0.94 
MIF vs. sCD74/MIF 0.66 
sCD74 vs. sCD74/MIF 1.02 
Figure 5B Effect of sCD74/MIF on WT 
Ctrl vs. MIF 0.11 
Ctrl vs. sCD74 1.05 
Ctrl vs. sCD74/MIF 3.91 
MIF vs. sCD74/MIF 3.27 
sCD74 vs. sCD74/MIF 1.86 
Figure 5C 
Effect of sCD74/MIF   
in Cd74-/- vs.  WT 
Control 0.00 
MIF 0.41 
sCD74 0.94 
sCD74/MIF 1.56 
Figure 5D 
Effect of sCD74/MIF on 
SB225002-pretreated WT 
Ctrl vs. MIF 0.24 
Ctrl vs. sCD74 1.11 
Ctrl vs. sCD74/MIF 2.71 
MIF vs. sCD74/MIF 2.05 
sCD74 vs. sCD74/MIF 1.77 
Figure 5E 
Effect of sCD74/MIF  
on  DMSO-pretreated WT 
Ctrl vs. MIF 0.23 
Ctrl vs. sCD74 0.58 
Ctrl vs. sCD74/MIF 3.42 
MIF vs. sCD74/MIF 5.59 
sCD74 vs. sCD74/MIF 2.83 
Figure 5F 
Effect of sCD74/MIF   
in WT+SB225002 vs.  
WT+DMSO 
Control 0.36 
MIF 0.12 
sCD74 0.58 
sCD74/MIF 1.10 
Figure 5G 
Effect of sCD74/MIF on  
AMD3100-pretreated WT 
Ctrl vs. MIF 1.95 
Ctrl vs. sCD74 0.88 
Ctrl vs. sCD74/MIF 4.06 
MIF vs. sCD74/MIF 0.86 
sCD74 vs. sCD74/MIF 2.09 
Figure 5H 
Effect of sCD74/MIF  
on ddH2O-pretreated WT 
Ctrl vs. MIF 0.30 
Ctrl vs. sCD74 0.32 
Ctrl vs. sCD74/MIF 4.33 
MIF vs. sCD74/MIF 3.87 
sCD74 vs. sCD74/MIF 1.93 
Figure 5I 
Effect of sCD74/MIF   
in WT+AMD3100 vs.  
WT+ddH2O 
Control 0.57 
MIF 1.99 
sCD74 0.57 
sCD74/MIF 0.96 
Figure 6A human MIF ELISA 
Healthy vs.CHD 3.35 
Healthy vs. HF 2.43 
CHD vs. HF 1.52 
Figure 6B human sCD74 ELISA Healthy vs.CHD 0.32 
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Healthy vs. HF 0.11 
CHD vs. HF 0.54 
Figure 6C sCD74/MIF ratio 
Healthy vs.CHD 1.02 
Healthy vs. HF 1.12 
CHD vs. HF 0.69 
Suppl. Figure 2A 
α-SMA 
Ctrl vs. MIF 0.66 
Ctrl vs. sCD74 0.04 
Ctrl vs. sCD74/MIF 0.10 
MIF vs. sCD74/MIF 0.37 
sCD74 vs. sCD74/MIF 0.08 
Col1a1 
Ctrl vs. MIF 0.53 
Ctrl vs. sCD74 0.25 
Ctrl vs. sCD74/MIF 0.97 
MIF vs. sCD74/MIF 0.50 
sCD74 vs. sCD74/MIF 0.68 
Fibronectin 1 
Ctrl vs. MIF 0.87 
Ctrl vs. sCD74 2.10 
Ctrl vs. sCD74/MIF 0.83 
MIF vs. sCD74/MIF 0.15 
sCD74 vs. sCD74/MIF 0.02 
Suppl. Figure 5A TNFα mRNA 
Ctrl vs. MIF 0.70 
Ctrl vs. sCD74 0.39 
Ctrl vs. sCD74/MIF 0.81 
MIF vs. sCD74/MIF 0.05 
sCD74 vs. sCD74/MIF 1.05 
Suppl. Figure 5B soluble TNFα 
Ctrl vs. MIF 0.23 
Ctrl vs. sCD74 0.29 
Ctrl vs. sCD74/MIF 0.38 
MIF vs. sCD74/MIF 0.62 
sCD74 vs. sCD74/MIF 0.67 
Suppl. Figure 5D Intracellular  TNFα at 10h 
Ctrl vs. MIF 0.60 
Ctrl vs. sCD74 1.36 
Ctrl vs. sCD74/MIF 1.19 
MIF vs. sCD74/MIF 0.09 
sCD74 vs. sCD74/MIF 0.12 
Suppl. Figure 5E 
 
Effects within the donor group 
after 6h 
Ctrl vs. MIF 0.16 
Ctrl vs. sCD74 0.49 
Ctrl vs. sCD74/MIF 1.76 
 
Effects within the recipient 
group after 6h 
Ctrl vs. MIF 0.06 
Ctrl vs. sCD74 0.44 
Ctrl vs. sCD74/MIF 0.61 
Effect of sCD74/MIF   
in donor vs. recipient group 
Ctrl vs. MIF 0.04 
Ctrl vs. sCD74 0.12 
Ctrl vs. sCD74/MIF 1.00 
Suppl. Figure 5F 
 
Effects within the donor group 
after 10h 
Ctrl vs. MIF 1.95 
Ctrl vs. sCD74 1.35 
Ctrl vs. sCD74/MIF 2.99 
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Effects within the recipient 
group after 10h 
Ctrl vs. MIF 0.07 
Ctrl vs. sCD74 0.29 
Ctrl vs. sCD74/MIF 1.75 
Effect of sCD74/MIF   
in donor vs. recipient group 
Ctrl vs. MIF 2.08 
Ctrl vs. sCD74 0.87 
Ctrl vs. sCD74/MIF 2.25 
Suppl. Figure 8A Oasl2 mRNA 
Ctrl vs. MIF 0.69 
Ctrl vs. sCD74 1.22 
Ctrl vs. sCD74/MIF 1.32 
MIF vs. sCD74/MIF 0.93 
sCD74 vs. sCD74/MIF 0.44 
Suppl. Figure 8B Tgtp2 mRNA 
Ctrl vs. MIF 1.03 
Ctrl vs. sCD74 1.02 
Ctrl vs. sCD74/MIF 1.10 
MIF vs. sCD74/MIF 0.31 
sCD74 vs. sCD74/MIF 0.14 
Suppl. Figure 8C Ccl2 mRNA 
Ctrl vs. MIF 1.07 
Ctrl vs. sCD74 0.56 
Ctrl vs. sCD74/MIF 1.83 
MIF vs. sCD74/MIF 0.41 
sCD74 vs. sCD74/MIF 1.46 
Suppl. Figure 8D Ccl7 mRNA 
Ctrl vs. MIF 1.41 
Ctrl vs. sCD74 1.36 
Ctrl vs. sCD74/MIF 3.65 
MIF vs. sCD74/MIF 1.18 
sCD74 vs. sCD74/MIF 2.82 
Suppl. Figure 15A 
WT: CD74 surface expression 
at 0.5h 
Ctrl vs. MIF 0.11 
Ctrl vs. sCD74 0.13 
Ctrl vs. sCD74/MIF 0.48 
MIF vs. sCD74/MIF 0.38 
sCD74 vs. sCD74/MIF 0.41 
Suppl. Figure 15B 
WT: CXCR2 surface 
expression at 0.5h 
Ctrl vs. MIF 0.49 
Ctrl vs. sCD74 0.12 
Ctrl vs. sCD74/MIF 0.84 
MIF vs. sCD74/MIF 0.35 
sCD74 vs. sCD74/MIF 0.81 
Cd74-/-: CXCR2 surface 
expression at 0.5h 
Ctrl vs. MIF 0.21 
Ctrl vs. sCD74 0.78 
Ctrl vs. sCD74/MIF 0.32 
MIF vs. sCD74/MIF 0.13 
sCD74 vs. sCD74/MIF 1.07 
Suppl. Figure 15C 
WT: CXCR4 surface 
expression at 0.5h 
Ctrl vs. MIF 0.80 
Ctrl vs. sCD74 0.12 
Ctrl vs. sCD74/MIF 0.75 
MIF vs. sCD74/MIF 0.16 
sCD74 vs. sCD74/MIF 0.82 
Ctrl vs. MIF 0.02 
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Cd74-/-: CXCR4 surface 
expression at 0.5h 
Ctrl vs. sCD74 0.25 
Ctrl vs. sCD74/MIF 0.03 
MIF vs. sCD74/MIF 0.02 
sCD74 vs. sCD74/MIF 0.25 
Suppl. Figure 15D 
WT: CD74 surface expression 
at 4h 
Ctrl vs. MIF 1.71 
Ctrl vs. sCD74 0.01 
Ctrl vs. sCD74/MIF 0.02 
MIF vs. sCD74/MIF 2.10 
sCD74 vs. sCD74/MIF 0.03 
Suppl. Figure 15E 
WT: CXCR2 surface 
expression at 4h 
Ctrl vs. MIF 0.33 
Ctrl vs. sCD74 0.11 
Ctrl vs. sCD74/MIF 1.59 
MIF vs. sCD74/MIF 1.20 
sCD74 vs. sCD74/MIF 2.00 
Cd74-/-: CXCR2 surface 
expression at 4h 
Ctrl vs. MIF 2.17 
Ctrl vs. sCD74 0.98 
Ctrl vs. sCD74/MIF 1.91 
MIF vs. sCD74/MIF 0.18 
sCD74 vs. sCD74/MIF 2.67 
Suppl. Figure 15F 
WT: CXCR4 surface 
expression at 4h 
Ctrl vs. MIF 4.11 
Ctrl vs. sCD74 2.82 
Ctrl vs. sCD74/MIF 5.20 
MIF vs. sCD74/MIF 2.49 
sCD74 vs. sCD74/MIF 3.60 
Cd74-/-: CXCR4 surface 
expression at 4h 
Ctrl vs. MIF 0.21 
Ctrl vs. sCD74 0.15 
Ctrl vs. sCD74/MIF 0.41 
MIF vs. sCD74/MIF 0.23 
sCD74 vs. sCD74/MIF 0.23 
Suppl. Figure 15G 
WT: CD74 surface expression 
at 8h 
Ctrl vs. MIF 1.07 
Ctrl vs. sCD74 0.27 
Ctrl vs. sCD74/MIF 5.62 
MIF vs. sCD74/MIF 5.14 
sCD74 vs. sCD74/MIF 2.26 
Suppl. Figure 15H 
WT: CXCR2 surface 
expression at 8h 
Ctrl vs. MIF 0.01 
Ctrl vs. sCD74 0.37 
Ctrl vs. sCD74/MIF 2.66 
MIF vs. sCD74/MIF 1.68 
sCD74 vs. sCD74/MIF 2.76 
Cd74-/-: CXCR2 surface 
expression at 8h 
Ctrl vs. MIF 1.18 
Ctrl vs. sCD74 0.53 
Ctrl vs. sCD74/MIF 1.15 
MIF vs. sCD74/MIF 0.04 
sCD74 vs. sCD74/MIF 1.47 
Suppl. Figure 15I 
WT: CXCR4 surface 
expression at 8h 
Ctrl vs. MIF 3.42 
Ctrl vs. sCD74 2.39 
Ctrl vs. sCD74/MIF 3.00 
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MIF vs. sCD74/MIF 0.36 
sCD74 vs. sCD74/MIF 1.47 
Cd74-/-: CXCR4 surface 
expression at 8h 
Ctrl vs. MIF 0.21 
Ctrl vs. sCD74 0.13 
Ctrl vs. sCD74/MIF 0.59 
MIF vs. sCD74/MIF 0.41 
sCD74 vs. sCD74/MIF 0.49 
Suppl. Figure 16A 
WT: CD74 surface expression 
at 5min 
Ctrl vs. MIF 1.67 
Ctrl vs. sCD74 2.08 
Ctrl vs. sCD74/MIF 2.65 
MIF vs. sCD74/MIF 0.37 
sCD74 vs. sCD74/MIF 0.32 
Suppl. Figure 16B 
WT: TLR2 surface expression 
at 0.5h 
Ctrl vs. MIF 0.28 
Ctrl vs. sCD74 0.35 
Ctrl vs. sCD74/MIF 0.63 
MIF vs. sCD74/MIF 0.43 
sCD74 vs. sCD74/MIF 0.39 
Cd74-/-: TLR2 surface 
expression at 0.5h 
Ctrl vs. MIF 0.63 
Ctrl vs. sCD74 0.01 
Ctrl vs. sCD74/MIF 0.68 
MIF vs. sCD74/MIF 0.14 
sCD74 vs. sCD74/MIF 0.65 
Suppl. Figure 16C 
WT: TLR4 surface expression 
at 0.5h 
Ctrl vs. MIF 0.07 
Ctrl vs. sCD74 0.13 
Ctrl vs. sCD74/MIF 0.21 
MIF vs. sCD74/MIF 0.29 
sCD74 vs. sCD74/MIF 0.35 
Cd74-/-: TLR4 surface 
expression at 0.5h 
Ctrl vs. MIF 0.14 
Ctrl vs. sCD74 0.67 
Ctrl vs. sCD74/MIF 3.62 
MIF vs. sCD74/MIF 1.19 
sCD74 vs. sCD74/MIF 0.50 
Suppl. Figure 16D 
WT: TNFRI surface 
expression at 0.5h 
Ctrl vs. MIF 0.17 
Ctrl vs. sCD74 0.14 
Ctrl vs. sCD74/MIF 0.09 
MIF vs. sCD74/MIF 0.08 
sCD74 vs. sCD74/MIF 0.23 
Cd74-/-: TNFRI surface 
expression at 0.5h 
Ctrl vs. MIF 1.81 
Ctrl vs. sCD74 3.98 
Ctrl vs. sCD74/MIF 2.91 
MIF vs. sCD74/MIF 0.28 
sCD74 vs. sCD74/MIF 0.00 
Suppl. Figure 16E 
WT: TLR2 surface expression 
at 4h 
Ctrl vs. MIF 1.23 
Ctrl vs. sCD74 0.72 
Ctrl vs. sCD74/MIF 1.25 
MIF vs. sCD74/MIF 0.61 
sCD74 vs. sCD74/MIF 0.88 
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Cd74-/-: TLR2 surface 
expression at 4h 
Ctrl vs. MIF 0.80 
Ctrl vs. sCD74 0.17 
Ctrl vs. sCD74/MIF 0.98 
MIF vs. sCD74/MIF 0.53 
sCD74 vs. sCD74/MIF 1.00 
Suppl. Figure 16F 
WT: TLR4 surface expression 
at 4h 
Ctrl vs. MIF 0.70 
Ctrl vs. sCD74 0.23 
Ctrl vs. sCD74/MIF 0.46 
MIF vs. sCD74/MIF 0.33 
sCD74 vs. sCD74/MIF 0.26 
Cd74-/-: TLR4 surface 
expression at 4h 
Ctrl vs. MIF 0.67 
Ctrl vs. sCD74 2.06 
Ctrl vs. sCD74/MIF 0.19 
MIF vs. sCD74/MIF 0.36 
sCD74 vs. sCD74/MIF 1.28 
Suppl. Figure 16G 
WT: TNFRI surface 
expression at 4h 
Ctrl vs. MIF 0.32 
Ctrl vs. sCD74 0.43 
Ctrl vs. sCD74/MIF 0.78 
MIF vs. sCD74/MIF 0.23 
sCD74 vs. sCD74/MIF 0.29 
Cd74-/-: TNFRI surface 
expression at 4h 
Ctrl vs. MIF 0.03 
Ctrl vs. sCD74 0.40 
Ctrl vs. sCD74/MIF 0.70 
MIF vs. sCD74/MIF 0.64 
sCD74 vs. sCD74/MIF 0.51 
Suppl. Figure 16H 
WT: TLR2 surface expression 
at 8h 
Ctrl vs. MIF 1.51 
Ctrl vs. sCD74 0.00 
Ctrl vs. sCD74/MIF 1.77 
MIF vs. sCD74/MIF 0.50 
sCD74 vs. sCD74/MIF 1.79 
Cd74-/-: TLR2 surface 
expression at 8h 
Ctrl vs. MIF 0.73 
Ctrl vs. sCD74 0.11 
Ctrl vs. sCD74/MIF 0.84 
MIF vs. sCD74/MIF 0.45 
sCD74 vs. sCD74/MIF 0.77 
Suppl. Figure 16I 
WT: TLR4 surface expression 
at 8h 
Ctrl vs. MIF 0.74 
Ctrl vs. sCD74 0.84 
Ctrl vs. sCD74/MIF 0.89 
MIF vs. sCD74/MIF 0.18 
sCD74 vs. sCD74/MIF 0.20 
Cd74-/-: TLR4 surface 
expression at 8h 
Ctrl vs. MIF 0.99 
Ctrl vs. sCD74 1.18 
Ctrl vs. sCD74/MIF 1.45 
MIF vs. sCD74/MIF 1.00 
sCD74 vs. sCD74/MIF 1.89 
Suppl. Figure 16J 
WT: TNFRI surface 
expression at 8h 
Ctrl vs. MIF 0.04 
Ctrl vs. sCD74 0.51 
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Ctrl vs. sCD74/MIF 0.19 
MIF vs. sCD74/MIF 0.22 
sCD74 vs. sCD74/MIF 0.62 
Cd74-/-: TNFRI surface 
expression at 8h 
Ctrl vs. MIF 0.86 
Ctrl vs. sCD74 2.23 
Ctrl vs. sCD74/MIF 0.53 
MIF vs. sCD74/MIF 0.09 
sCD74 vs. sCD74/MIF 0.19 
 
  
D
ow
nloaded from
 http://ahajournals.org by on October 23, 2019
 
 
Figure S1. Experimental Setup. 
 
Cardiac myofibroblasts were randomized into four groups, which were incubated either with medium 
(group1: control), 8 nmol/L rMIF (group2: rMIF), 40 nmol/L sCD74 (group3: sCD74) or five-fold molar 
excess of sCD74 to rMIF (group4: sCD74/rMIF) for 24 h. For inhibition studies in WT myofibroblasts, 
cells were treated with either the inhibitor compound (AMD3100, SB225002, Nec1s) or the appropriate 
solvent as control (ddH2O or DMSO). Following 1 h of incubation, both solvent and inhibitor-pretreated 
cells were stimulated either with medium, rMIF, sCD74 or sCD74/rMIF and maintained for further 20-
24 h. 
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Figure S2. Treatment with sCD74/MIF did not induce de-differentiation of myofibroblasts to a 
quiescent fibroblast. 
 
Following treatment of cardiac myofibroblasts with vehicle, sCD74, rMIF or 
sCD74/rMIF for 24 h, mRNA expression of (A) α-smooth muscle actin (α-SMA), (B) 
collagen 1α1 (Col1α1) and (C) fibronectin 1 (FN1) were assessed via RT-qPCR 
method. Data represent mean±SEM of six independent experiments and were 
analyzed with a two-tailed, unpaired t-test corrected for multiple comparison (n=5). 
*p<0.05 vs. control. 
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Figure S3. Representative blots of cleaved caspase-3 and GAPDH 10 h after treatment with 
increasing concentrations of sCD74 either with or without MIF. 
 
WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) Full-length and cleaved caspase-3 and (B) GAPDH were assessed 10 h 
after stimulation by Western blotting. 
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Figure S4. Representative blots of pRIP3, RIP3 and GAPDH 10 h after treatment with increasing 
concentrations of sCD74 either with or without MIF. 
 
 
WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) Phosphorylation of RIP3, (B) total RIP3 and (C) GAPDH were assessed 
10 h after stimulation by Western blotting. 
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Figure S5. TNFα could not be identified as mediator of sCD74/MIF-induced 
necroptosis. 
 
WT fibroblasts were stimulated solitarily or simultaneously with 40 nmol/L sCD74 and 8 nmol/L 
rMIF. (A) mRNA levels (via RT-PCR) as well as (B) extracellular (via ELISA) and (C-D) 
intracellular protein levels of TNFα (via Western blotting) were determined. Instead of showing 
the whole blot, relevant bands were cut out and arranged in the respective order. The uncut 
blots are shown in Figure S6). (E-F) For the supernatant transfer experiments, WT 
myofibroblasts were stimulated solitarily or simultaneously with sCD74 and rMIF (donor). After 
supernatant was transferred to untreated WT cells (recipient). Both donor and recipient cells 
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were maintained for further 20-24 h followed by Trypan blue staining and automated counting. 
Data represent mean±SEM of at least (A) eight, (B) six, (D) eight, (E) ten and (F) eight 
independent experiments. Data were analyzed with a two-tailed, unpaired t-test and corrected 
for multiple comparison (A-D: n=5; E-F: n=7) using Bonferroni posttest. §§§p<0.001 vs. control 
of donor cells; $p<0.05 vs. control of recipient cells; **p<0.01 donor vs. recipient. 
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Figure S6. Representative blots of TNFα and GAPDH 10 h after treatment with increasing 
concentrations of sCD74 either with or without MIF. 
 
WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) TNFα and (B) GAPDH were assessed 10 h after stimulation by Western 
blotting. 
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Figure S7. sCD74/MIF-dependent gene expression differs largely from those induced by MIF or 
sCD74. 
(A) Venn diagram of overlapping and unique effects of sCD74, rMIF and sCD74/rMIF on gene 
expression. A total of 115 genes with a fold change ≥1.5 among the differentially expressed genes are 
represented. Venn diagram was generated using Vennplex. (B)The genes with at least 1.5-fold 
change following rMIF treatment compared to control were depicted. The marginal overlap between 
rMIF and sCD74/rMIF stimulation were marked. (C) The genes with at least 1.5-fold change following 
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sCD74 treatment compared to control were depicted. Type I IFN-induced genes are labeled as black 
bars. Genes labeled as grey bars seem not to contribute to specialized function and pathways. 
Independent triplicates were performed. The corresponding p-values are listed in Table S1. 
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Figure S8. Treatment with sCD74/MIF significantly upregulates gene expression of cytokines. 
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RT-qPCR was performed with the cDNA and Taqman probes. Data represent mean±SEM of at least 
four independent experiments and were analyzed with a two-tailed, unpaired t-test with multiple 
correction (n=5). $p<0.05; $$$p<0.001 vs. control respectively; **p<0.01 vs. sCD74. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S9. Representative blots of pAKT, AKT and Tubulin 30 min after treatment with increasing 
concentrations of sCD74 either with or without MIF. 
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WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) Phosphorylation of AKT, (B) total AKT and (C) Tubulin were assessed 
30 min after stimulation by Western blotting. 
 
 
 
Figure S10. Representative blots of pAKT, AKT and Tubulin 10 h after treatment with increasing 
concentrations of sCD74 either with or without MIF. 
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WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) Phosphorylation of AKT, (B) total AKT and (C) Tubulin were assessed 
10 h after stimulation by Western blotting. 
 
 
 
 
Figure S11. Representative blots of pp38, p38 and GAPDH 30 min after treatment with increasing 
concentrations of sCD74 either with or without MIF. 
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WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) Phosphorylation of p38, (B) total p38 and (C) GAPDH were assessed 
30 min after stimulation by Western blotting. 
 
 
 
 
 
 
Figure S12. Representative blots of pp38, p38 and GAPDH 10 h after treatment with increasing 
concentrations of sCD74 either with or without MIF. 
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WT myofibroblasts were stimulated with medium and 40 nmol/L sCD74 either in the absence or 
presence of 8 nmol/L rMIF. (A) Phosphorylation of p38, (B) total p38 and (C) GAPDH were assessed 
10 h after stimulation by Western blotting. 
 
 
 
 
 
 
Figure S13. Basal surface expression levels of MIF receptors CD74, CXCR2 and CXCR4 in WT 
and Cd74-/- myofibroblasts. 
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WT and Cd74-/- myofibroblasts were detached by scraping and cell surface expression of (A-C) CD74, 
(D-F) CXCR2 and (G-I) CXCR4 receptor were analyzed by flow cytometry. The median fluorescence 
intensity (MFI) of isotype control was subtracted from MFI of its appropriate antibody preparation. Data 
represent mean±SEM of at least three independent experiments. 
 
 
 
 
 
 
 
Figure S14. Basal surface expression of TLR2, TLR4 and TNFRI in WT and Cd74-/- myofibroblasts. 
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WT and Cd74-/- myofibroblasts were detached by scraping and cell surface expression of (A-C) TLR2, 
(D-F) TLR4 and (G-I) TNFRI receptor were analyzed by flow cytometry. The median fluorescence 
intensity (MFI) of isotype control was subtracted from MFI of its appropriate antibody preparation. Data 
represent mean±SEM of at least three independent experiments. 
 
 
 
 
 
Figure S15. sCD74/rMIF induces rapid and prolonged chemokine receptor internalization. 
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WT and Cd74-/- myofibroblasts were stimulated with sCD74 either alone or with MIF for (A-C) 0.5 h, (D-
F) 4 h and (G-I) 8 h. Subsequently, cells were detached by scraping and cell surface expression of (A, 
D, G) CD74, (B,E,H) CXCR2 and (C,F,I) CXCR4 receptor were analyzed by flow cytometry. The relative 
fluorescence intensity (RFI) of isotype control was subtracted from MFI of its appropriate antibody 
preparation. Data represent mean±SEM of at least three independent experiments. $p<0.05, $$p<0.01 
vs. control respectively. 
 
 
 
 
Figure S16. Increased TLR2 expression following sCD74/rMIF stimulation. 
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WT and Cd74-/- myofibroblasts were stimulated with sCD74 either alone or with MIF for (A) 5 min (B-
D) 0.5 h, (E-G) 4 h and (H-J) 8 h. Subsequently, cells were detached by scraping and cell surface 
expression of (A) CD74, (B, E, H) TLR2, (C,F,I) TLR4 and (D,G,J) TNFRI receptor were analyzed by 
flow cytometry. The relative fluorescence intensity (RFI) of isotype control was subtracted from MFI of 
its appropriate antibody preparation. Data represent mean±SEM of at least three independent 
experiments. 
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